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Development of Synthetic Polymers for Bone Tissue Engineering:
Engineering the Degradation Rate
By
Kirsten N Cicotte
B.S., Biomolecular Science and Chemistry, Clarkson University, 2005
Ph.D., Engineering, University of New Mexico, 2013

ABSTRACT
In this work the development, synthesis, and characterization of
biodegradable synthetic polymers, poly (butylene fumarate) (PBF) and the
copolymer poly (butylene fumarate)-co-(butylene maleate) (PBFcBM) is described.
The unsaturated linear polyesters were synthesized via two synthetic routes,
including an acid catalyzed transesterification reaction of (Z)-4-((4-hydroxybutan-2yl)oxy)-4-oxobut-2-enoic acid which was formed via a ring opening reaction of maleic
anhydride with 1,3-butylene glycol (BG) and reacting the acid chlorides, maleoyl
chloride (MCl) and fumaryl chloride (FCl) with BG. Both methods introduce the cis
(maleate) functionality into the polymer backbone, however a controlled fumarate to
maleate ratio was only obtained via the acid chloride starting monomers.
The PBF polymer differs from the previously examined PPF polymer through
an additional methylene (CH2) unit in the polymer backbone. This methylene unit
increases the chain length between the crosslinkable fumarate (C=C) double bond.
Because of this, It was hypothesized that PBF allow for a greater water ingress and
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therefore an increased rate of degradation relative to PPF. Results from In vitro
accelerated degradation studies confirmed our hypothesis.
An in vitro cytocompatibility study with the murine cell line MC3T3-E1
demonstrated that there were no cytotoxic components that leached from
crosslinked PBF networks. In addition, the PBF crosslinked networks were
assessed for the ability to support mesenchymal stem cell (MSC) differentiation
down the osteogenic lineage. Cellular adhesion and proliferation as well as the
presence of alkaline phosphatase and extracellular calcium of MSCs cultured under
osteogenic medium conditions on crosslinked PBF networks were evaluated.
Methodology to fabricate highly interconnected porous mats comprised of
nano to micro sized fibers was developed using the photo initiator bis(2,4,6trimethybenzoyl) phenoylphosphine oxide (BAPO) to crosslink the fumarate-based
fibers in situ while electrospinning. Characterization showed that the alterations to
the general electrospinning technique could be used to spin polymers with glass
transition (Tg) temperatures below room temperature without the use of a sacrificial
polymer.
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Chapter 1. Introduction
Bone undergoes maintenance, resorption and rearrangement through the

interaction of osteoblasts (bone forming), osteocytes (bone maintaining) and
osteoclasts (bone resorbing) cells. This remodeling cycle allows for repair and
regeneration following most injuries, such as small-scale fractures.1-3 However,
each year up to 15 million people receive traumatic bone injuries and 1.5 million
bone fractures occur which cannot be remedied by the intrinsic capacity for bone to
self-repair, leaving a non-union which requires surgical intervention.4, 5
Non-union defects in bone arise from diseases, traumatic injuries as well as
tumor resection.6-8 In order to heal this non-union defect a material must be used to
fill the defect. The current standard followed to do this is through bone grafting. Bone
grafting inserts harvested bone in a defect area; sources include: 1) autografts, or
donor bone removed from the patient 2) allografts, or bone from another human,
typically a cadaver and 3) xenografts, or bone from a different species.4, 9
Of these sources, autografting is the gold standard and preferred over the
other options due to the inherent structural stability and osteogenic (bone producing)
ability.10 Regardless, both allograft and autograft options are accompanied by
severe limitations due to limited supply of donor bone,as well as the significant risks
associated with the surgery itself.11 These risks include infection at the grafting site,
formation of a seroma, and development of a hematoma or disease transmission.12,
13

Due to the risks associated with grafting, alternative approaches are gaining much

attention, as there is an obvious clinical need. One such approach is tissue
engineering (TE), involving biology, engineering, materials and medicine to
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accommodate the shift in healthcare from replacement to towards
repair/regeneration.

Tissue Engineering
Tissue engineering (TE) uses engineered materials with complex
architectures to mimic the 3D cellular microenvironment, thereby providing suitable
mechanical properties for the tissue environment that is being mimicked (NIH).14
This interdisciplinary approach combines: 1) cells isolated from a patient source,
allowing seeding of specific cell populations, 2) a matrix (scaffold) capable of
providing appropriate mechanical and structural support, and finally 3) biomolecular
cues, such as growth factors to promote tissue formation with the appropriate
function.15 The TE paradigm is depicted in Figure 1.1.

Scaffold Material Selection
There is a need to identify, develop and broaden materials for use in TE
scaffolds beyond the options currently under development or commercially available
options. At a minimum, scaffold materials must be biocompatible, biodegradable
and be capable of having sufficient mechanical properties for use in orthopedic
(bone) applications. Many materials, including ceramics, metals and polymers have
been evaluated as a scaffolding material. Drawbacks associated with ceramics and
metals include being non degradable (both), brittle (ceramics) and mismatched in
mechanical properties compared to bone (metals).16, 17 Polymeric biomaterials,
either natural or synthetic in origin, have shown initial success in orthopedic tissue
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engineering. Natural polymers offer inherent biocompatibility, but lack suitable
mechanical properties, while synthetic polymeric materials can be more easily
tailored to fit the specific needs required by the tissue environment.18, 19 Synthetic
polymers for bone tissue engineering (BTE) which are subject to hydrolytic
degradation due to the functionality in the polymer backbone include poly αhydroxyesters20-27, poly(orthoesters)28-30, polyanhydrides31-34,
polyhydroxyalkanoates35-41(Figure 1.2). These synthetic polymers have not been
limited to use for BTE applications, poly α-hydroxyesters including poly(glycolic acid)
(PGA), poly(lactic acid) (PLA) and the copolymer poly(lactic)-co-(glycolic acid)
(PLGA) are approved for use by the Federal Drug Administration (FDA). These
esters have a tunable degradation rate, dependent on the ratio of lactic acid:glycolic
acid, and are seen in clinical application as dissolvable sutures.
Although many polymers offer biodegradability, several of the aforementioned
polyester classes lack the appropriate mechanical properties to match native bone
(Table 1.1). Mechanical properties of bone span a large range, this is due to the
location, age and overall health of the bone. The tensile strength and modulus range
from 3.1 - 180 GPa and 3.9 – 71 GPa, for dense bones (cortical), respectively.3, 9
Where compressive strength and modulus for less dense bone
(trabecular/cancellous) can be seen in the range from 0.2 – 300 MPa and 1.5 – 9500
MPa (with midrange of 5-10 MPa and 50-100 MPa), respectively.9 Therefore, these
are the ranges in mechanical properties, which need to be achieved for optimal
repair and use in BTE applications. The polymer poly(propylene fumarate) (PPF) is
being extensively researched due to the ability to achieve high compressive
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strengths which are inline with native bone, and are still able to undergo
biodegradation.

Poly(Propylene Fumarate) (PPF)
The unsaturated linear polyester, PPF has been synthesized via poly
condensation reactions from the monomers of propylene glycol (PG) and a variety of
fumarate derivatives, including diethyl fumarate (DEF)42-45, fumaryl chloride44, 46, 47,
fumarate dicarbodiimide44, fumaric acid44, 48, 49(Figure 1.3). The PPF polymeric
backbone contains both ester linkages, which are susceptible to hydrolysis as well
as a carbon-carbon double bond. After synthesis, PPF can be covalently crosslinked
either thermally50 or photochemically51 through the carbon- carbon double bond of
the fumarate functional group.
The choice of synthetic route as well as the choice of initiator system leads to
crosslinked networks that display varying mechanical properties. Fisher et al 52
synthesized PPF (high and low molecular weight, MW) from monomers DEF and
propylene glycol (PG), followed by crosslinking with the photoinitiator . Measured
compressive moduli were in the range of bone with a modulus of 195.3 ± 17.5 MPa
and fracture strength of 68.8 ± 9.4 MPa. To increase mechanical properties,
composite of PPF crosslinked networks with the inclusion of beta tricalcium
phosphate (β-TCP) were prepared. Inclusion of β-TCP yielded a crosslinked
polymer network whose modulus and yield strength were increased to ~1200 MPa
and ~300 MPa.3 These experimental values demonstrate that PPF crosslinked
networks have sufficient mechanical properties and display similar properties to
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bone (trabecular/cancellous). As PPF has been synthesized and researched to
display high mechanical properties over the other materials used in BTE
applications, a consideration also has to be the effect of increased mechanical
properties and how that modulates ester hydrolysis.
High modulus PPF materials such as those fabricated by Fisher et al have
been evaluated both in vitro and in vivo. Although the polymer displayed mechanical
properties similar to that of bone, the rate of bone growth was greater than that of
scaffold degradation. The material displayed little to no degradation after 50 weeks
in vitro53 and 18 weeks in vivo.54 To try and address this, PPF copolymers have
been synthesized, including poly(ε-caprolactone) (PPF-PCL),55, 56 poly(ethylene
glycol) (PPF-PEG) and oligo(polyethylene glycol) fumarate (OPF).57, 58 These
crosslinked polymeric networks display mechanical properties in the range of 1.8145 MPa

Scaffold Requirements
Material selection is not the only factor that has to be considered when
designing a synthetic replacement to autologous bone grafting. Besides the scaffold
needing to be mechanically suitable, the key factors to an ideal scaffold for bone
tissue engineering applications are: 1) it is comprised of macro (pore size > 100 µm)
and micro (pore size < 20 µm) architecture, 2) highly interconnected pores with a
large surface area to volume ratio, allowing for cellular infiltration, integration and
vascularization, 3) favorable chemical environment to promote cellular attachment,
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growth and differentiation, 4) controlled degradation kinetics, with out compromising
the mechanical suitability and 5) a sterile environment for cells.4, 59
Again, PPF has been shown in many publications to be biocompatible and
biodegradable. The degradation products that result from ester hydrolysis of PPF
are PG and fumaric acid, a commonly used diluent in drug formulations and a
naturally occurring substance found in the Krebs cycle.60 In addition, it has also
been shown both in vitro61, 62 and in vivo63, 64 to be osteoconductive (ability to provide
the appropriate scaffold or template for bone formation), by providing a scaffold for
osteoblasts to infiltrate, lay down extracellular matrix (ECM) and generate new bone.

Scaffold Fabrication
As synthesized, PPF has a glass transition temperature (Tg) below room
temperature (RT), making it a liquid at room temperature (RT). This characteristic
allows for either pre-fabrication of scaffolds for implant and well as an injectable
system which can be crosslinked in-situ.65-68 Porous PPF and PPF composite
scaffolds have been fabricated using solvent casting/leaching69-71, stereolitography7275

and high internal phase emulsions (polyHIPEs).76 All of these techniques are

capable of making highly porous structures, yet each has some potential drawbacks
and limitations. Solvent casting involves incorporation of particles (ie. sodium
chloride, NaCl) prior to crosslinking followed by leaching using solvent, creating a
network with controlled porosity and pore size, but random spatial organization.77
Stereolithography, a term that broadly describes rapid prototyping (RP) or solid free
form (SFF), allows computer aided generation of more complex architecture
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scaffolds, but fabrication is both costly and time consuming.77 Although overcoming
some of the limitations seen in other processing techniques, the technique has many
advantages and disadvantages including fine structure control and cost. More
recently gaining attention is polyHIPEs, or high internal phase emulsions, due to the
ability to create highly porous interconnected scaffold. However, these scaffolds do
not include the complex micro and macro structure that is needed to mimic the
native ECM.
	
  
Conclusions
There is an apparent clinical need for an alternative to current bone grafting
with over 500,000 grafting procedures being performed yearly in the United States
alone.78 The interdisciplinary field of tissue engineering (TE) can provide a possible
solution through the use of a patient’s own cells, a synthetic scaffolding material and
various signaling molecules (ie. growth factors).
Focus on polymeric materials that undergo degradation, provide
biocompatibility, serve as an osteoconductive matrix and are mechanically suitable
are being widely explored. Extensive research is being carried out on the fumaratebased unsaturated polyester poly(propylene fumarate) (PPF) due to the initial in vitro
and in vivo success. This polymer system also is attractive due to the ability to form
crosslinked polymeric networks either pre-implantation or as an injectable. Although
PPF has moved the field of bone tissue engineering (BTE) forward in the last 20
years, there are still properties that are non-ideal. Primarily, the mismatch of
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scaffold degradation and bone formation being at the forefront of properties that
needs to be addressed.
Further bridging the scientific, engineering and clinical disciplines will allow for
movement towards an ideal scaffold with mechanical suitability, biocompatibility with
the desired degradation profile. This task is non-trival, there are many factors such
as robustness, reproducibility and standardization that must be addressed before a
product is approved by the Federal Drug Adminstration (FDA) for clinical use.

	
  

	
  

Figure 1.1. Schematic representation of the tissue engineering (TE) paradigm,
involving isolation of cells from the patient, followed by expansion ex vivo , scaffold
seeding where cells and growth factors are loaded on a three dimensional porous
scaffold and implanted. In the case of bone, the 3D scaffold is placed in the nonunion. Over time, bone formation occurs within the defect area and the temporary
scaffold degrades, resulting in complete repair/regeneration of functional bone.
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Table 1.1. Summary of bones (cortical and cancellous) mechanical properties.
(Adapted from Porter, 2009, #9)
Property
Compressibe strength (MPa)
Tensile strength (Mpa)
Strain to toughness (%)

	
  

Cortical bone

Cancellous bone

100-230
50-150
1-3

2-12
10-20
5-7

Fracture toughness (Mpa m1/2)

2-12

--

Young’s modulus (Mpa)

7-30

0.5-0.05
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Chapter 2. Specific Aims
The overall objectives of this research are to development and characterize a

crosslinkable, biocompatible polymeric system with tunable degradation for use in
the fabrication of scaffolds to be used in bone tissue engineering (BTE). The worked
described herein leverages the extensive prior research on the fumarate-based
poly(propylene fumarate) (PPF) to develop a biocompatible and biodegradable
polyester through modifications in the polymer backbone. Engineering of the
backbone will alter the degradation kinetics of the crosslinked networks without
compromising the polymers workability (ease of processing), crosslinkability or the
crosslinked networks mechanical suitability.
In the course of this work, the following specific aims were identified and
investigated:
1. Synthesize and characterize a novel fumarate-based polymer system
(Chapter 3).
2. Characterize network structures of the crosslinked polymer network, both
initially and during degradation. (Chapter 4)
3. Validate cytocompatibility and the ability to support bone formation
(osteoconductivity)(Chapter 5).
4. Develop inexpensive techniques for the fabrication of 3D polymeric scaffolds
(Chapter 6).

The results obtained through the proposed specific aims will contribute to the
current class of synthetic biocompatible polymers being used in orthopedic or, more
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generally, tissue engineering applications and drug delivery. The synthesis of new
fumarate-based synthetic polyesters with “tunable” degradation rates will lead to a
better understanding of how polymer composition can be tailored to achieve a better
match of bone formation and scaffold degradation.
Initial broader impacts can be seen in the form of established collaborations.
These collaborations look at using our inexpensive polymer processing techniques
in a pre-clinical setting (in vivo animal models).

1. Development and evaluation of polydimethylsiloxane (PDMS) and PBF as
potential peripheral nerve interface (PNI) materials (Chapter 7 Part I).

2. Development and evaluation of PDMS scaffolds with controlled pore size for
implantation in an ischemic mouse model to evaluate neovascularization
(Chapter 7 Part II).
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Chapter 3. Synthesis and Characterization of Novel Fumarate-based
Polymeric System

1. Introduction
Poly(propylene fumarate) (PPF) is an unsaturated linear polyester, which has
been extensively studied for use as a degradable biomaterial for orthopedic tissue
engineering applications. PPF degrades through hydrolysis of the ester linkages
yielding biocompatible degradation products.1 Since the introduction of PPF in
19872, 3, it has been synthesized from various fumarate derivatives including diethyl
fumarate (DEF)4-7, fumaryl chloride (FCl)5, 8, fumarate dicarbodiimide5, and fumaric
acid.5, 9, 10 The resulting polymers have been shown to form crosslinked networks
which are both biocompatible and promote bone formation in vitro and in vivo
regardless of the synthetic methodology used to create the unsaturated polyester.2,
11-13

Crosslinked PPF has been shown to be a suitable biomaterial as it is easy to

process and it degrades into non-cytotoxic products. However, a drawback is that
the degradation rate is slow relative to the rate of bone formation. In vitro studies
show little or no degradation of PPF up to 50 weeks,14-16 while in vivo studies have
shown little or no degradation up to 18 weeks. The in vivo degradation studies used
porous PPF scaffolds placed in a critical sized defect rabbit radii model, where initial
bone growth into the scaffold was observed at the scaffold/defect edges however
scaffold infiltration was not observed. This observation suggests that the
degradation rate of the scaffold was sufficiently slow to impede bone formation.13
Attempts to increase the rate of ester hydrolysis of PPF by chemical
alterations to the fumarate-based polymer have included altering the molecular
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weight14,

17

, introducing more hydrolytic groups18,

19

, modifying the crosslinked

polymer network via surface modification after the crosslinking event20-22 and
introducing porosity.23 Our interest and the current work has focused on increasing
the degradation rate of crosslinked unsaturated fumarate-based polyesters via
modification of the polymer backbone. To introduce these modifications we have
substituted the biocompatible butylene glycol (BD) has been substituted in place of
propylene glycol (PD) as a starting material, providing an extra methylene group in
the resulting polymer.24,

25

In addition to a diol substitution, two synthetic routes

have been identified to incorporate cis (maleate) along with the trans (fumarate)
functionality. We hypothesize that these modifications will increase ester hydrolysis
by either 1) increasing the distance between hydrolysable esters and reduce steric
hindrance, or 2) introduce chain “kinks” resulting in void spaces that will increase the
ability of water infiltration into crosslinked networks.
Herein we have identified synthetic routes to yield the homopolymers of
poly(propylene fumarate) (PPF) and poly(butylene fumarate) (PBF) as well as the
copolymers of poly(propylene fumarate)-co-(propylene maleate) (PPFcPM) and
poly(butylene fumarate)-co-(butylene maleate) (PBFcBM). PPF and PBF were
made from maleic anhydride (MA) over the more expensive DEF and FCl starting
monomers which are currently used.26, 27 Selection of MA allows for ring opening
polymerization (ROP) to yield the copolymer or homopolymer by controlling the cis
to trans isomerization of the more energetically favorable fumarate functionality.28, 29
However, this route can produce polymers with various material properties based on
the catalyst selected and the feed ratio of MA and either PD or BD.30 The
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copolymers of PPFcPM and PBFcBM as well can vary greatly due to reaction
conditions, resulting in various maleate:fumarate (M:F) ratios in the resulting
polymer. Leading to the identification and development of a novel controlled
synthetic route where the F:M ratio in the resulting copolymer will be dictated by the
starting ratio of monomers used. To do this the acid chlorides of FCl and maleyol
chloride (MCl) are used with the diol (BD) and the reaction kept at low temperatures
in order to limit the cis to trans isomerization, offering control over F:M based on
MCl:FCl starting ratios.

2. Materials and Methods
2.1. Chemicals and Reagents
p-Toluensulfonic acid (TsOH), monohydrate 99%, extra pure was purchased
from Acros. Anhydrous magnesium sulfate (MgSO4), certified ACS plus sulfuric acid
(H2SO4), silica gel sorbent (200-425 mesh), HPLC grade ethyl acetate (EtOAc),
reagent grade triethylamine (TEA), and potassium hydroxide (KOH) were purchased
from Fisher. Maleic anhydride ( briquettes 99%, MA), 1,2-propanediol (99%, PD),
1,3-butanediol (Reagent Plus®, 99%, BD), Zinc chloride (anhydrous powder
99.995% trace metals, ZnCl2), Iron (III)Chloride (reagent grade 97%), potassium
bromide (KBr) and anhydrous dichloromethane (DCM) were purchased from Aldrich.
Chlorofom, (for HPLC, CHCl3) and fumaryl chloride (95%, FCl) were purchased from
Acros Organics. Thionyl chloride (SOCl2) was purchased from Alfa Aesar. All
chemicals were used as received from suppliers.
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2.2. Equipment
Nuclear magnetic resonance (NMR) was carried out on a 400 MHz Bruker
DRX-AVANCE. Proton chemical shifts (δ) are reported as shifts from the internal
standard tetramethylsilane (TMS). Infrared Spectroscopy (IR) was carried out on a
Nicolet 6700 FTIR equipped with a continuum microscope. Gel Permeation
Chromatography (GPC) molecular weight determinations were performed by GPC
using a Polymer Labs 220 PL-GPC equipped with a UV-Vis detector. Two columns
(PLgel 5 µm MiniMIX-C, 250 × 4.6 mm) and a guard column (PLgel 5 µm MiniMIX-C,
50 × 4.6 mm) were used in series with a flow rate of 0.4 mL/min and a run pressure
of 6.0 MPa. Relative molecular weights were determined using polystyrene
standards with a narrow molecular weight distribution (Fluka ReadyCal 4002,000,000). Chloroform was used as the eluent (0.4 mL/min), and measurements
were performed at 35°C. Differential Scanning Calorimetry (DSC) was carried out on
TA Instruments DSC Q100.

2.3. Polymer Synthesis: Ring Opening Polymerization (ROP) from MA
2.3.1. Homopolymer Synthesis
2.3.1.1. Poly(1,2-Propylene fumarate) (PPF) Synthesis from MA
To a 100 ml round bottom flask equipped with a stir bar and distillation head,
MA (10.0 g, 102 mmol), PD (7.8 g, 102 mmol), and TSOH (0.02 g, 0.1 1 mmol) were
added. The reaction mixture was heated to 250°C with stirring. After 3 hr, the
reaction was allowed to cool to RT. The resulting viscous crude polymer was
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dissolved in ethyl acetate (50 mL) and washed with distilled water
(50 ml, 3×). The organic layer was dried over anhydrous MgSO4, filtered and solvent
removed in vacuo to yield a slightly yellow viscous polymer.
IR (neat) 2984.1, 1714.7, 1645.4, 1454.7, 1379.0, 1290.2, 1255.5,
1153.4, 1116.2, 1075.9, 1022.5, 979.1, 837.3, 753.5, 666.4cm-1. 1H-NMR (400MHz,
CDCl3) δ 6.88–6.78 (m, -CH=CH-), 5.25–5.2 (m, -CH(CH3)), 4.68–2.8 (m,-OCOCH2-), 1.43–1.15 (m, (CH3)CH2). GPC (1 mg/ml,CHCl3) Mw 949 Mn 473.
Tg (°C) -15.24.
2.3.1.2. Poly(1,3-Butylene Fumarate) (PBF) Synthesis from MA
To a 100 ml round bottom flask equipped with a stir bar and distillation head,
MA (10.0 g, 102 mmol), BD (9.2 g, 102 mmol), and TSOH (0.02 g, 0.1 1 mmol) were
added. The reaction mixture was heated to 250°C with stirring. After 3 hr, the
reaction was allowed to cool to RT. The resulting viscous crude polymer was
dissolved in ethyl acetate (50 mL) and washed with distilled water
(50 mL, 3×). The organic layer was dried over anhydrous MgSO4, filtered and
solvent removed in vacuo to yield a slightly yellow viscous polymer. IR (neat)
3430.5, 3231.7, 3081.2, 3027.5, 2979.1, 2937.7, 2684.8, 1743.8, 1696.8, 1646.1,
1456.4, 1382.9, 1356.2, 1317.9, 1277.1, 1189.5, 1107.7, 1046.1, 989.1, 877.4,
850.8, 756.6 and 665.7 cm-1. 1H NMR (400 MHz, CDCl3) δ 6.91-6.73 (m, 2H), 5.135.07 (m, 1H), 4.32-4.15 (m, 2H), 2.05-1.77 (m, 2H), 1.32-1.10 (m, 3H). Mw 1777,
PDI 1.78. Tg (°C) -21.64.
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2.3.2. Copolymer Synthesis
2.3.2.1. General One-Step Aziotropic Distillation: Method A
Monomers, toluene, and catalyst were added to a round bottom flask
equipped with stir bar and Dean-Stark (DS) trap for azeotropic distillation. The
reaction was allowed to proceed at a maximum temperature 110°C, until no more
distillate (water) was collected. The reaction mixture was cooled to RT and the
toluene was removed in vacuo. The crude polymer was then dissolved in EtOAc and
washed with distilled water (dH2O) (3×). The organic layer was then dried over
anhydrous MgSO4 and solvent again removed in vacuo.

2.3.2.1.1. Poly(1,2-Propylene Fumerate)-co-(1,2-Propylene Maleate) (PPFcPM)
MA (10.0 g, 102 mmol), PD (7.8 g, 102 mmol), toluene(30–50 mL), and the
appropriate catalyst, TsOH (0.2g, 1.0 mmol), H2SO4 (1 drop, 18N), ZnCl2 (0.14 g,
1.0mmol) or FeCl3 (0.17 g, 1 mmol), were added to a 100mL round bottom flask
equipped with stir bar along with DS trap and condenser. The reaction mixture was
allowed to progress overnight. The reaction was ended and brought to RT, upon
cooling toluene was removed in vacuo. The crude polymer was then dissolved in
ethyl acetate (50 mL) and washed with water (50 ml, 3x). The organic layer was
dried over MgSO4 with filtration and the solvent was removed in vacuo to yield a
clear viscous polymer.

PPFcPM synthesized with TsOH:
IR (neat) 3490.0, 3058.6, 2983.4, 1711.9, 1643.6, 1455.3, 1384.2, 1252.6, 1077.7,
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983.6, 828.7, 777.3 cm-1. 1H-NMR (400 MHz,CDCl3) δ 7.17–7.14 (m, Ar), 7.09–7.03
(m, Ar), 6.83–6.76 (m, trans -CH1=CH), 6.27–6.13 (m, cis –CH=CH-),5.19–5.17 (bs,
-CH(CH3)), 4.34–3.61 (m, -OCO-CH2-), 2.26 (s, CH3-Ar), 1.25–1.03 (m, (CH3)CH2-).
GPC (1 mg/ml, CHCl3) Mw 995 Mn728. Tg (°C) -40.38.

PPFcPM synthesized with ZnCl2:
IR (neat) 3516.3,3079.6, 2984.3, 2943.7, 2883.4, 1711.1, 1644.0, 1452.5,1381.1,
1356.2, 1289.2, 1251.9, 1224.0, 1149.6, 1116.0,1075.9, 1019.6, 978.3, 835.7,
773.5, 668.1 cm-1.1HNMR(400 MHz, CDCl3) δ 7.22–7.20 (m, Ar), 7.14–7.10 (m, Ar),
6.90–6.76 (m, trans –CH=CH-), 6.23–6.20 (m, cis –CH=CH-), 5.27–5.07 (m, CH(CH3)), 4.40–4.02 (m, -OCO-CH2-), 2.32 (s, CH3-Ar), 1.51–1.23 (m, (CH3)CH2=).
GPC (1 mg/ml, CHCl3) Mw 1297 Mn 824. Tg (°C) -18.66.

PPFcPM synthesized with FeCl3:
IR (neat) 3445.0,3235.5, 3081.1, 2985.9, 2661.0, 2362.5, 1716.2, 1751.0,1700.4,
1646.7, 1455.9, 1386.3, 1355.4, 1324.4, 1279.4,1190.8, 1121.8, 1080.2, 990.2,
838.6, 775.3 cm-1. 1HNMR (400 MHz, CDCl3) δ 6.93–6.83 (m, trans –CH=CH), 6.33–
6.23 (m, cis –CH=CH-), 5.27–5.10 (m, -CH(CH3)), 4.40–4.10 (m, -OCO-CH2-), 1.44–
1.23 (m, (CH3)CH2-). GPC (1 mg/ml, CHCl3) Mw1871 Mn 1043. Tg (°C) -37.58.

PPFcPM synthesized with H2SO4:
IR (neat) 3526.2, 3079.3, 2984.1, 1716.1, 1645.5, 1558.5, 1541.9, 1508.1,1456.2,
1379.8, 1253.1, 1217.4, 1150.1, 1113.8, 1074.7,977.1, 833.2, 773.2 cm-1. 1H-NMR
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(400 MHz, CDCl3) δ 7.23–7.20 (m, Ar), 7.15–7.10 (m, Ar), 6.88–6.82 (m, trans –
CH=CH), 6.34–6.24 (m, cis –CH=CH-), 5.24 (bs, -CH(CH3)), 4.77–4.00 (m, -OCOCH2-), 2.32 (s, CH3-Ar), 1.44–1.21 (m, (CH3)CH2-). GPC (1 mg/ml, CHCl3) Mw 672
Mn 330. Tg (°C) -12.86.

2.3.2.1.2. Poly(1,3-Butylene Fumerate)-co-(1,3-Butylene Maleate) (PBFcBM)
MA (10.0 g, 102 mmol), BD (9.2 g, 102 mmol) toluene (30-50 ml) TsOH (0.2
g, 1.0 mmol), were added to a 100 ml round bottom flask equipped with stir bar
along with Dean Stark trap and condenser. The reaction mixture was allowed to
progress overnight. The reaction was ended and brought to RT. Upon cooling
toluene was removed in vacuo. The crude polymer was then dissolved in ethyl
acetate and washed with water (3×). The organic layer was dried over MgSO4 and
solvent removed in vacuo, resulting in a clear viscous polymer.

2.3.2.2. General Two-Step Aziotropic Distillation: Method B
Monomers and toluene were added to a round bottom flask. The reaction
mixture was heated to 50°C and stirred overnight. The reaction mixture was allowed
to cool to RT and the toluene was removed in vacuo. The reaction flask was then
equipped with a DS trap and condenser to collect water through azeotropic
distillation during the second reaction. Next, a protic acid catalyst was added to the
product of the first reaction, and the mixture heated to a maximum temperature of
110°C, until the appropriate volume of water was collected. The reaction mixture
was allowed to cool to RT, the solvent was removed in vacuo, and the crude
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polymer was dissolved in EtOAc and washed with distilled water (3×). Finally, the
organic layer was dried over anhydrous MgSO4 and solvent removed in vacuo.

2.3.2.2.1. Poly(1,2-Propylene Fumerate)-co-(1,2-Propylene Maleate) (PPFcPM)
MA (10.0 g, 102 mmol), PD (7.8 g, 102 mmol) and toluene (15 mL) were
added to a 100mL round bottom flask equipped with a stir bar. Under a nitrogen (N2)
blanket, the reaction heated to 50°C with stirring was allowed to run overnight. The
next day, the reaction mixture was cooled to RT and the solvent removed in vacuo.
The reaction flask was then equipped with a DS trap and condenser. Toluene and
either tosic acid (0.2 g, 1 mmol) or sulfuric acid (1 drop, 18 N) was added to the
product of the first reaction. The reaction was allowed to run until the expected
amount of distillate (water) was collected via the DS trap. The reaction was allowed
to come to RT and the solvent was removed in vacuo. The crude polymer was then
dissolved in EtOAc (50 mL) and washed with water (50 mL, 3×). The organic layer
was dried over MgSO4 with filtration and the solvent was removed in vacuo to yield
a slightly yellow viscous polymer.

PPFcPM synthesized with TsOH:
IR (neat) 2985.9,1721.6,1691.3,1644.4,1454.6,1381.1, 1289.9, 1252.0,
1215.8, 1152.4, 1116.1, 1075.4, 979.0, 838.2, 774.3,736.5, 669.0 cm-1. 1H-NMR
(400 MHz, CDCl3) δ 6.86–6.83 (m, trans –CH=CH-), 6.29–6.23 (m, cis –CH=CH-),
5.24 (bs, -CH(CH3)), 4.78–3.44 (m, -OCO-CH2), 1.32–1.17 (m, (CH3)CH2-). GPC (1
mg/ml, CHCl3) Mw 11,388 Mn 2347. Tg (_C) -13.78.
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PPFcPM synthesized with H2SO4:
IR (neat) 2985.7, 1717.7, 1643.6, 1454.7, 1382.5, 1253.8, 1151.8, 1116.5,1075.3,
978.7, 889.8, 838.1, 7775.0, 734.6, 694.8 cm-1. 1H-NMR (400 MHz, CDCl3) δ 7.24–
7.21 (m, Ar), 7.16–7.11 (m, Ar), 6.83 (s, trans –CH=CH-), 6.25 (s, cis –CH=CH-) ,
5.26 (bs, -CH(CH3)), 4.78–2.75 (m, -OCO-CH2-), 2.33 (s, CH3-Ar), 1.33–1.17 (m,
(CH3)CH2-). GPC (1 mg/ml, CHCl3) Mw 5520 Mn 739. Tg (°C) -13.78

2.3.2.2.2. Poly(1,3-Butylene Fumerate)-co-(1,3-Butylene Maleate) (PBFcBM)
MA (10.0 g, 102 mmol), BD (9.2 g, 102 mmol) and toluene (15 ml) were
added to a 100 ml round bottom flask equipped with a stir bar. Under a nitrogen
blanket, the reaction heated to 50°C with stirring was allowed to run overnight. The
next day, the reaction mixture was allowed to cool to RT and the solvent was
removed in vacuo. The reaction flask was then equipped with a Dean Stark trap and
condenser. TsOH (0.2g, 1mmol) was added to the product of the first reaction and
the reaction was allowed to run until appropriate amount of distillate was collected
via the Dean Stark trap. The reaction was allowed to come to RT and the solvent
was removed in vacuo. The crude polymer was dissolved in ethyl acetate (50 mL)
and washed with water (50 mL, 3×). The organic layer was dried over MgSO4 with
filtration and the solvent was removed in vacuo to yield a slightly yellow viscous
polymer.
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2.4. Polymer Synthesis: Controlled Synthesis from Acid Chlorides
2.4.1. Monomer Synthesis
2.4.1.1. Synthesis of Maleic Acid (MAc)
MA (0.25 mol, 25 g) and H2O (0.25 mol, 4.6 g) were added to 100 ml round
bottom flask equipped with a stir bar and allowed to react overnight under N2. Upon
completion, the product was filtered and washed with CHCl3 and dried yielding 25 g
(87% yield). 1H NMR (400 MHz, CDCl3) δ 6.08 (2H, s), 4.80 (2H, s).

2.4.1.2. Synthesis of Maleoyl Chloride (MCl) (3)
MAc (69 mmol, 8.0 g) was added to a round bottom flask equipped with stir
bar. The atmosphere was removed and replaced with N2 (3×) and the flask was
cooled in an ice water bath. SOCl2 (138 mmol, 16.4 g) was added and the reaction
was stirred overnight. Upon completion of the reaction, excess SOCl2 was removed
in vacuo producing a white powder. Anhydrous CHCl3 was added and the residual
acid was removed by filtration through a schlenk filter. Solvent was removed in
vacuo to yield a white powder, which was carried on to the next step without further
purification. Melting Point (°C) 54-55; 1H NMR (400 MHz, CDCl3) δ 7.03 (2H, s).

2.4.2. Homopolymer Synthesis
2.4.2.1. General Synthesis with no Proton Scavenger
MCl was added to a 250 ml 3-neck round bottom flask, equipped with stir bar,
addition funnel, N2 sparge and hose inlet/outlet adapter. Atmosphere was removed
and replaced with N2 (3×), DCM (30 ml) was added to the round bottom containing
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MCl and FCl, to the addition funnel was added BD and DCM (10 ml) under nitrogen.
Upon addition of both dichloride monomers (FCl and MCl), BD and 20 ml DCM were
added drop wise to the reaction (at 0°C), sweeping away the HCl (gas) from the
reaction flask via the hose inlet/outlet adapter to a beaker containing a KOH (aq)
base trap. Each of the PBFcBM copolymers where synthesized using this general
setup.

2.4.2.1.1. Poly(1,3-Butylene Fumarate) (PBF) Synthesis from FCl
FCl (65.4 mmol, 10 g) was added to a 250 ml 3-neck round bottom flask
equipped with a stir bar, addition funnel, and a N2 sparge adapter. Atmosphere was
removed and replaced with N2 (3×) and DCM (30 ml) was added and the flask was
cooled to 0°C. BD (65.4 mmol, 5.9 g) and DCM (10 ml) were added to the addition
funnel. The solution of BD was added drop wise to the MCl/DCM solution. The
evolved HCl(g) was swept using a N2 sparge to a KOH(ag) base trap. The reaction
was washed with dH2O (3×) dried over MgSO4 and solvent removed in vacuo.
IR (neat) 2980.2, 2935.2, 2362.3, 2335.6, 1724.1, 1646.3, 1558.7, 1456.5, 1380.9,
1356.6, 1300.9, 1261.5, 1225.3, 1163.1, 1105.0, 983.0, 872.5, 773.8, 668.6 cm-1; 1H
NMR (400 MHz, CDCl3) δ 6.89-8.80 (m, 2H), 5.10 (bs, 1H), 4.68-4.10 (bm, 2H)
2.06-2.00 (bm, 2H) 1.30-1.19 (m, 3H); Mn 834 PDI 1.89. Tg (°C) -34.67.

2.4.2.1.2. Poly (1,3-Butylene Maleate) (PBM)
MCl (65.4 mmol, 10 g ) was added to a 250 ml 3-neck round bottom flask
equipped with a stir bar, addition funnel, and a N2 sparge adapter. Atmosphere was
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removed and replaced with N2 (3×) and DCM (30 ml) was added and the flask was
cooled to 0°C. BD (65.4 mmol, 5.9 g) and DCM (10 ml) were added to the addition
funnel. The solution of BD was added drop wise to the MCl/DCM solution. The
evolved HCl(g) was swept using a N2 sparge to a KOH(ag) base trap. The reaction
was washed with dH2O (3×) dried over MgSO4 and solvent removed in vacuo.
IR (neat) ; 2978.9, 1726.6, 1637.9, 1413.9, 1215.9, 1168.8, 1042.2, 982.4, 821.3,
484.4, 411.0 (Fumarate:Maleate, 9:91) Tg (°C) -29.31

2.4.2.2. Copolymer Synthesis
2.4.2.2.1. Synthesis of 75/25 PBFcBM
MCl (16.34 mmol, 2.5 g) was added to a 250 ml 3-neck round bottom flask
equipped with a stir bar, addition funnel, and a N2 sparge adapter. Atmosphere was
removed and replaced with N2 (3×), FCl (51.5 mmol, 7.9 g) was added to the round
bottom containing MCl. DCM (30 ml) was added to the round bottom containing MCl
and FCl, to the addition funnel was added BD (67.84 mmol, 6.11 g) and TEA (74.6
mmol, 7.55 g), under nitrogen and on ice/water bath BD was slowly added to the
round bottom and the reaction was allowed to progress overnight. Upon completion
the reaction was washed with dH2O (3×) dried over MgSO4 and solvent removed in
vacuo, resulting in a yellow viscous polymer.
IR (neat) 3506.1, 2976.8, 1719.8, 1644.4, 1457.3, 1383.0, 1356.3, 1300.7, 1162.9,
1102.0, 981.6, 911.5, 850.3, 821.5, 757.8, 668.5, 418.4 cm-1; 1H NMR (400 MHz,
CDCl3) δ 6.87-6.76 (m, 2H), 6.43-6.28 (m, 2H), 5.13 (bs, 1H), 4.43-3.65 (bm, 2H)
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2.05-1.74 (bm, 2H) 1.37-1.20 (m, 3H); (Fumarate:Maleate, 78:22); Mn 804 PDI
1.67; Tg (°C) -35.39.

2.4.2.2.2. Synthesis of 50/50 PBFcBM
Synthesized following same procedure as 75/25 PBFcBM using the following
amounts, MCl (32.7 mmol, 5 g), FCl (34.3 mmol, 5.25 g) and BD (67 mmol, 6.03 g).
IR(neat) 2979.5, 2363.1, 1722.9, 1642.7, 1455.9, 1385.5, 1301.0, 1261.9, 1224.4,
1165.0, 1102.7, 1051.8, 980.7, 820.4, 756.8, 667.8 cm-1; 1H NMR (400 MHz, CDCl3)
δ 6.82-6.78 (m, 2H), 6.37-6.19 (m, 2H), 5.17-5.11 (bs, 1H), 4.29-4.06 (bm, 2H) 2.041.96 (bm, 2H) 1.34-1.20 (m, 3H); (Fumarate:Maleate, 51:49); Mn 697 PDI 1.58; Tg
(°C) -37.68.

2.4.2.2.3. Synthesis of 25/75 PBFcBM
Synthesized following same procedure as 75/25 PBFcBM using the following
amounts, MCl (49.0 mmol, 7.5 g), FCl (17.2 mmol, 2.6 g) and BD (66.2 mmol, 5.97
g). IR (neat) 3446.9, 2974.4, 1718.9, 1642.3, 1457.2, 1409.4, 1382.8, 1301.1,
1263.1, 1220.2, 1168.2, 1043.2, 982.7, 910.3, 821.5, 757.4, 668.0 cm-1;

1

H NMR

(400 MHz, CDCl3) d 6.88-6.83 (m, 2H), 6.46-6.25 (m, 2H), 5.32-5.17 (m, 1H), 4.483.95 (bm, 2H) 2.05-1.78 (bm, 2H) 1.41-1.24 (m, 3H); (Fumarate:Maleate, 27 :73) ;
Mn 746 PDI 1.30; Tg (°C) -39.12.

2.5. Polymer Characterization
2.5.1. Determination of Polymer Density
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Density was measured in weight at room temperature (RT) using 1ml glass vials

(Cole Parmer, Cat # WU-98815-00) relative to the same volume of distilled water in
the glass vial (d= 1.0 g/ml).

2.5.2. Determination of Extinction Coefficients for Cis and Trans Double Bond
Absorptions
FTIR was carried out by forming 1 wt% polymer/KBr pellets with a path length of
0.3105 mm, scanning from 1200-1300 wavenumbers/centimeter (resolution = 1, 64
scans). The IR Extinction coefficients were determined for each homopolymer (PBF
and PBM) at 1215 and 1260 wavenumbers respectively. These extinction
coefficients were used to quantify the amount of fumarate to maleate in each
copolymer.

3. Results and Discussion
3.1. Polymer Synthesis: Ring Opening Polymerization (ROP) from MA
The homopolymers of poly(propylene fumerate) (PPF), poly(butylene
fumarate) (PBF) as well as the accompanying copolymers of poly(propylene
fumerate)-co-(propylene maleate) (PPFcPM) and poly(butylene fumerate)-co(butylene maleate) (PBFcBM) were synthesized via step growth polycondensation
reactions (Scheme 3.1). The glass transition temperatures of all polymers
synthesized were below room temperature and ranged from -7°C to -40°C (Table
3.1). The neat polycondensation reaction at high temperatures yielded the all
fumarate based homopolymers (PPF and PBF) were synthesized via the protic acid
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catalyzed neat reaction of maleic anhydride (MA) with 1,2-propanediol (PD) or 1,3butanediol (BD) at high temperatures (~250°C), whereas the copolymers (PPFcPM
and PBFcBM) were obtained using a protic acid catalyst at lower temperatures (85–
110°C).

3.1.1. Copolymers Synthesized via Method A and Method B
Synthesis of PPFcPM and PBFcBM was carried out via a one-step (Method
A) and two-step (Method B) azeotropic distillation procedure (Scheme 3.2). The first
method (Method A) used to synthesize the copolymer involved a protic acid or Lewis
acid catalyzed polymerization reaction carried out at 85°C to 110°C to azeotropically
remove water. The second method (Method B) involved an initial ring opening
reaction carried out at 50°C without the use of a catalyst followed by an acid
catalyzed condensation reaction in combination with azeotropic removal of water.
The ratio of fumerate to maleate (F:M) in the resulting polymer was influenced
by both temperature and catalyst (Table 3.2). Polymer synthesized at high
temperatures(neat) produced only PPF and PBF, however the molecular weight
(MW) was low presumably due to side reaction	
  products which changed the
monomer stoichiometry. As the catalytic activities of each catalyst are slightly
different, only direct comparison between polymerization techniques using the same
catalyst can be made. For example, polymer synthesized at low temperatures
according to Method A using TsOH yielded a polymer with 33% fumerate, whereas
Method B yielded polymer that contained 55% fumerate (Table 3.1). Polymer formed
with mostly maleate had a very low Tg when compared to polymer having a much
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smaller amount of maleate. Furthermore, there appears to be no correlation
between Tg and molecular weight as each polymer is a random copolymer. PPFcPM
synthesized using sulfuric acid as the catalyst resulted in toluene inclusion due to
Friedel-Craft alkylation.4 The influence of temperature and catalyst was also
observed in all of the one step azeotropic distillation scenarios, thus providing a
system which has the ability to be adjusted.
The MW’s of all polymers produced were determined through gel permeation
chromatography (GPC) using narrow weight distribution polystyrene
as the standards. PPF synthesized according to Method A had an average
molecular weight (Mn) of 720, with PBF having an Mn of 536. The MW did not
increase with longer reaction times (data not shown). The low MW is consistent with
the initial production of PPFcPM and PBFcBM oligomers which thermally isomerizes
to the more stable fumerate form. Presumably the high temperature results in both
isomerization and side reactions that limit the polymer molecular weight by changing
the step growth stoichiometry. PPF synthesized in this fashion is about 70% lower in
molecular weight than other reported synthesis26, however PPF is isolated via a two
step synthesis in the previously reported synthesis. PPFcPM synthesized through
one step synthesis (Method A) also resulted in polymers with low molecular weights
(Table 3.1). To increase the Mn of our polyester, a two step synthesis (Method B)
was developed. Method B again produced the copolymers PFcPM and PBFcBM,
however in comparison to Method A the F:M ratio decreased. This decrease can be
attributed to the initial ring opening of the MA at the lower temperature (50°C) prior
to aziotropic distillation. The copolymer molecular weight were significantly higher
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than the homopolymers (PPF,PBF) and are summarized in Table 3.2.	
  

3.2 Polymer Synthesis: Controlled Synthesis from Acid Chlorides
Several ratios of fumaryl chloride to maleoyl chloride (FCl:MCl) (75:25, 50:50 and
25:75) were used with BD to yield PBFcBM with known F:M in the final polyester
(Scheme 3.2). 1H NMR was used to confirm the ratio of fumarate to maleate
functionality through integration of the olefin peaks at 6.8-6.9 ppm (fumarate, F) and
6.2-6.3 ppm (maleate, M) (Figure 3.1). All of the polymers had slightly lower
amounts of maleate functionality, which is consistent with a small amount of thermal
isomerization to the more stable fumarate functional group. All of the PBFcBM
copolymers synthesized here were evaluated using gel permeation chromatography
(GPC) as well as differential scanning calorimetry (DSC) in order to determine
molecular weight (Mn) and glass transition temperature (Tg) of the various
fumarate:maleate (F:M) polymers synthesized (Table 3.2). The molecular weights
were in the range of 746 to 834 with a PDI ranging from 1.30 to 1.89. The molecular
weights of all the polymers were low, indicating oligomers and not polymers, which is
not unexpected given that the reaction mechanism for the esterification reaction is
step growth. Variation from a 1:1 ratio of reactants results in inhibition of high
molecular weight polymers for step growth mechanisms. All of the oligomers had Tg
values which were well below that of room temperature and as the maleate
functionality was increased the Tg was shifted more negative from -34.67 (0%
maleate) to -35.39°C (25% maleate) to -37.68°C (50% maleate) to -39.12°C (75%
maleate).

	
  

	
  

32

3.3. Determination of Polymer Density
The density of each oligomer was determined and a clear trend was observed. As
the amount of maleate increased relative to fumarate, the density of the polymer
decreased (Table 3.2). This observation is consistent with a decrease in packing
density as more maleate is included in the backbone of the polymer. As the amount
of cis double bond incorporated into the backbone of the polymer increased more
chain packing defects were induced.

3.4. Determination of Cis and Trans by FT-IR
Fourier transform infrared (FT-IR) data was collected in the spectral region
ranging from 1200 to 1300 wavenumbers/cm to corroborate the 1H NMR
determinations of F:M ratio. It has been previously reported that the fumarate and
maleate absorb at 1260 and 1215 wavenumber/cm, respectively. FTIR spectra were
obtained for each of the fumarate-based oligomers, poly(butylene fumarate)(PBF)
and poly(butylene maleate) (PBM), as well as all of the oligomers with varying F:M
ratios (Figure 3.2 ). Extinction coefficients were determined using Beers Law. The
extinction coefficients (ε) for maleate and fumarate were calculated using the
homopolymers of PBM and PBF, using the following equation:

!=

! − !!
!"
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Where A is the absorbance maximum of the peak (maleate or fumarate) and A0 is
the absorbance value at the baseline of the given peak, c is the molar concentration
of polymer/sample and l is the path length. Solving the equation for εmaleate and
εfumarate yielded 7.56 x 103 mol-1cm-1 and 6.30 x 103 mol-1cm-1 respectively. The
extinction coefficients were used to calculate the percentage of fumarate and
maleate in all of the oligomer samples. The percentage of fumarate in each
oligomer was determined by FTIR agreed closely with percent fumarate values
determined by 1H NMR analysis (Figure 3.3).

4. Conclusions
Poly(propylene fumarate) (PPF) and poly(propylene-fumarate)-copoly(propylene-maleate) (PPFcPM) were successfully synthesized using maleic
anhydride (MA) and 1,2-propanediol (PD),via a step growth polycondensation using
the protic acid catalysts p-toluensulfonic acid (TsOH)and sulfuric acid (H2SO4) and
Lewis acid catalysts ZnCl2 and FeCl3. In addition to PPF and PPFcPM,
substituation of 1,3-butanediol (BD) for PD resulted in successful synthesis of
poly(butylene fumarate) (PBF) and poly(butylene fumarate)-co-poly(butylene
maleate) (PBFcBM) by transesterfication with TsOH as the catalyst.
Although successful maleate functionality was introduced in the polymer
backbone via the ring opening polymerization (ROP) from MA, this synthetic route
did not offer fine control over the resulting polymers fumarate:maleate (F:M) ratio.
To address this, a novel synthetic route starting from the acid chlorides of fumaryl
and meleoyl chloride was developed. We have demonstrated control over the F:M
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ratio by carrying out the polymerization of PBFcBM at low temperatures in order to
inhibit the thermal isomerization of the maleate to the more stable fumarate. The
polymerization scheme is very versatile and can be used with any diol in order to
produce a polyester copolymer with both maleate and fumarate functionality.
Increasing the maleate concentration relative to the fumarate concentration in the
backbone of the polymer resulted in polymers that contained kinks in the chain
packing and thus lowered the density of the final polymers. Control of the cis to
trans double bond ratio represents a novel methodology to control polymer
degradation.
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Scheme 3.1. Synthetic route followed in order to make the homopolymer (PPF and
PBF), from MA (1) and PD (2a) or BD (2b). As well as the copolymers (PPFcPM
and PBFcBM) using the same starting materials (1 and 2a,b) and forming the
intermediate (3).
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Scheme 3.2. Synthesis route followed in order to make MCl (1) from maleic acid,
followed by copolymer synthesis of PBFcBM, from dichloride starting materials FCl
(2) and MCl (1) with BD (3).
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Figure 3.1. 1H NMR of PBFcBM, where the peak at 6.8-6.9 ppm corresponds to the
fumarate olefins and the peak at 6.1-6.3 indicates the olefins associated with the
maleate. All reflect PBFcBM with varying fumarate:maleate ratios (A) 75:25, (B)
50:50 and (C) 25:75.
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Figure 3.2. FTIR spectra for all homopolymers and copolymers in the region of
1200-1300 cm-1. The maleate absorption occurs at ~1220 cm-1 and fumarate
absorption occurs at ~1260 cm-1.

Figure 3.3. The observed percent fumarate in each polymer relative to initial
stoichiometry as determined by FTIR (extinction coefficient) and 1H NMR analysis
(F:M olefin peak integration)
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Table 3.1. Summary of PPF and PPFcPM reaction conditions and polymer
characterization.
Catalyst

Method A

Method B

Fumarate:Maleate

Tg
(°C)

Mn

TsOH
TsOH

Reaction
Temperature
(°C)
250
85-110

1
0.5

-15.24
-40.38

473
728

H 2SO 4
ZnCl 2
FeCl 3
TsOH
H 2SO 4

85-110
85-110
85-110
50/85-110
50/85-110

3.82
8.62
6.54
1.25
2.5

-13.72
-18.66
-37.58
-13.78
-13.65

330
824
1043
2347
1739

Table 3.2. Summary of PBF and PBFcBM polymer characterization.
Fumarate:Maleate
(Starting Material)
100:0
75:25
50:50
25:75

Fumarate:Maleate
(Product)
100:0
78:22
51:49
27:73

Tg
(°C)
-34.67
-35.39
-37.68
-39.12

Mn

PDI

834
804
697
746

1.89
1.67
1.58
1.3

Density
(g/ml)
1.207
1.175
1.114
1.077
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Chapter 4. Crosslinked Network Characterization and In Vitro Degradation of
Photo Crosslinked Poly(Propylene Fumarate) and Poly(Butylene Fumarate)

1. Introduction
The body is constructed of biodegradable materials, allowing cells to remove
and replace old and defective tissue.1 In addition, the ideal scaffold to be employed
as a synthetic bone graft alternative would not only be biocompatible and
osteoconductive, but also have mechanical suitability and controlled degradability.
Ideal polymer degradation would occur in such a way that there would be gradual
load transfer from the scaffold to the bone as well as increasing space for bone
growth.2, 3
Major polymeric degradation mechanisms can be broken into four mechanism
based on the processing conditions and environment. These mechanisms are: 1)
hydrolytic, or degradation by water interaction, 2) oxidative, those polymers which
interact with oxidant produced by the tissue, 3) enzymatic, and 4) physical
degradation, due to mechanical loading or wear.4, 5 Hydrolytic degradation, the
primary form considered when developing biodegradable synthetic polymeric
materials, can have different modes of degradation. These modes, surface erosion
or bulk degradation, are determined by the rate of water diffusion into the bulk
polymer and the rate of chain cleavage by water ions. Surface erosion displays
exterior degradation with little to no ingress (penetration) into the bulk, where bulk
degradation water penetrates the entire structure and degrades the entire polymeric
network simultaneously (Figure 4.1).6-8
Bulk degradation is employed in bone tissue engineering (BTE) applications
the scaffold must be osteoconductive, allowing the anchoring of cells (osteoblasts),
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which would not occur with a material whose surface is continually eroding.3 This
mechanism of degradation has been displayed by the unsaturated linear polyester
poly(propylene fumarate) (PPF) both in vitro and in vivo.9, 10 The hydrolytic
degradation of the ester functionality displayed in PPF can be altered based on
polymer characteristic such as molecular weight, monomer selection and catalyst
used during synthesis.11, 12 PPF can be crosslinked using either thermally or
photochemically initiated radicals polymerizing the carbon-carbon double bond.
Selection of initiator system as well as crosslinking efficiency/density can alter the
rate of degradation, or ester hydrolysis.12
A drawback is that the degradation rate is slow relative to the rate of bone
formation. In vitro studies show little or no degradation of PPF up to 50 weeks,9
while in vivo studies have shown little or no degradation up to 18 weeks. The in vivo
degradation studies used porous PPF scaffolds placed in a critical sized defect
rabbit radii model, where initial bone growth into the scaffold was observed at the
scaffold/defect edges, however, scaffold infiltration was not observed. This
observation suggests that the degradation rate of the scaffold was sufficiently slow
to impede bone formation.13 In order to address this, researchers have made
copolymers of PPF with poly(e-caprolactone) (PPF-PCL)14, poly(ethylene glycol)
(PPF-PEG) and oligo(polyethylene glycol) fumarate (OPF).15, 16 These crosslinked
polymeric networks yielded compressive moduli from as low as 1.8 MPa17, which is
much lower than the 50- 100 MPa for trabecular bone.18 Therefore a sacrifice in
mechanical properties for increased rate of degradation is an area where
development is needed.
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Recently, we have developed another fumarate-based polymer poly(butylene

fumarate) (PBF) and poly(butylene fumarate)-co(butylene maleate) (PBFcBM) as
described in Chapter 3.19 By substituting butylene glycol (BG) for the propylene
glycol (PG), used to synthesize PPF, an additional methylene unit (-CH2) is
introduced between the crosslinkable carbon-carbon double bonds. We
hypothesized that the rate of ester hydrolysis would increase due to the addition of a
methylene unit in the polymer backbone. This increase in the rate of ester
hydrolysis increases the rate of degradation over the currently well-explored PPF
without compromising the mechanical properties.

2. Materials and Methods
2.1. Chemicals and Reagents
Tridecafluoro-1,1,2,2-tetrahydrooctyl trichlorosilane was purchased from
Gelest. Phosphate buffered saline (10X, PBS) solution, sodium phosphate
(monobasic anhydrous) and phosphoric acid (ACS grade) were purchased from
Fisher. Ammonium hydroxide (ACS grade) was purchased from EMD Chemicals.
Sodium hydroxide (1N, NaOH), dichloromethane (DCM), toluene, phenylbis(2,4,6trimethylbenzoyl)-phosphine oxide (97%, BAPO) were purchased from Sigma. All
chemicals were used as received from suppliers. Poly(propylene fumarate) (PPF)
and poly(butylene fumarate) (PBF) were synthesized as previously described in
Chapter 3.

2.2. Equipment
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Polymer characterization was performed using the equipment detailed in

Chapter 3. Glass molds (1 mL, Cat # WU-98815-00) were purchased from Cole
Parmer. Ultra Violet (UV) dosages were supplied using a UV Fusion ® System
(Fusion Inc.) and measured using a UV PowerPuck® (EIT). Differential Scanning
Calorimetry (DSC) was carried out on TA Instruments DSC Q100. Pellets for IR
were pressed using a manual pellet press (Carver). High Performance Liquid
Chromatography (HPLC) was carried out on an Agilent 1200 (Agilent Technologies).
Samples for degradation studies were cut to size using a wet saw (TechCut5™)
from Allied High Tech, Inc. Compressive moduli were determined following ASTM
D695-02a using an Instron 5500R with TestWorks 4 software. Accelerated
degradation samples were incubated using a Major Scientific (MS) incubator
equipped with temperature control and orbital shaker. Dimensional analysis was
measured with digital calipers purchased from Flexbar®. Degradation samples
masses were measured using a precision balance (Mettler-Toledo, #AB304S/FACT).

2.3. Polymer Synthesis
Both PPF and PBF were prepared as previously reported and described in
Chapter 3. In brief, MA, PD or BD and ZnCl2 were added to a 250 mL round bottom
flask equipped with a stir bar and distillation head. The reaction mixture was heated
to ~250 °C through the use of a silicon oil bath with stirring, while distillate (water)
was collected. Upon completion (distillate collection ceased), the reaction was
allowed to come to room temperature (RT). The crude polymer was dissolved in
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chloroform (CHCl3) (250 mL) and washed with water (250 mL, 3×). The organic
layer was dried over MgSO4 and solvent removed in vacuo, resulting in a yellow
viscous polymer.
GPC (1 mg/ml in CHCl3) PPF: Mw 1851 repeat unit = 12; PBF: Mw 2213 repeat unit
= 13

2.4. Network Characterization
2.4.1. Heat Capacity to Determine Crosslinking Efficiency
Differential scanning calorimetry (DSC) was used to measure heat capacity, a
method to estimate the crosslinking density of a network due to changes in polymer
degrees of freedom.20, 21 Crosslinked PPF and PBF were compared to the noncrosslinked starting polymers and the change in heat capacities (Cp) was used to
determine the degree of crosslinking. DSC thermograms were collected as a
function of temperature on ~10 mg samples at a heating rate of 10°C/min from -90°C
to 400°C followed by cooling from 400°C to -90°C at 10°C/min, this cycle was
repeated 3× on the same polymer sample. Heat capacity (Cp), or specific heat
capacity, was calculated by integration of the area under the curve, comparing
crosslinked PPF and PBF with uncrosslinked PPF and PBF using the following
equation:
Cp  =  

Heat  Flow  
  ×  K  
Heating  Rate
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Where heat flow, or change in enthalpy of the sample is obtained in W/g for the
specimen, heating rate is specific to the °C/min which is used and K is the calibration
constant for the DSC instrument being used and is dimensionless.

2.4.2. Infrared Spectroscopy (FT-IR) to Determine Crosslinking Efficiency
To carry out FT-IR , 5.0 wt% polymer/KBr pellets with a path length of 0.32
mm were prepared using a pellet press (6,000 lbs for 1 min). The resulting sample
pellet was then scanned from 1600-1800 wavenumbers/centimeter (resolution = 1,
64 scans). The IR extinction coefficients were determined for each uncrosslinked
polymer (PPF and PBF, n = 3 for each) at ~1645 wavenumbers. The extinction
coefficients (ε) for the fumarate peak was calculated using Beer’s Law:

ε  =

  A-‐Ao
  
cl

Where A is the absorbance maximum of the fumarate peak, A0 is the absorbance
value at the baseline of the given peak at 1645 cm-1, c is the molar concentration of
olefin/g sample (3.2 x 10-5 mol/g for PPF and 2.9 x 10-5 mol/g for PBF), and l is the
path length (0.32 mm). These extinction coefficients were then used to quantify the
concentration of double bonds which remained in the crosslinked PPF and PBF
samples. To do this, 0.5 wt% crosslinked polymer/KBR pellets were prepared and
FTIR was carried out in the same fashion as the uncrosslinked polymers. The
crosslinking density (X) is then calculated by the following equation:
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X  =  

cx
    
c0

Where the concentration of remaining double bonds, as calculated by the
crosslinked polymer samples (cx) is divided by the initial concentration of double
bonds in the uncrosslinked polymer samples (c0).

2.4.3. High Performance Liquid Chromatography (HPLC) to Determine Crosslinking
Efficiency
To carry out HPLC, uncrosslinked and crosslinked polymer samples of both
PPF and PBF were degraded completely in basic conditions using a previously
identified procedure. Briefly, 0.5 mg of polymer was placed in 10 ml of 1N NaOH in
a 20 ml scintillation vial, followed by degradation at 60°C under gentle agitation.
Prior to placement in degradative conditions, crosslinked PPF and PBF networks
were ground using a mortar and pestle to increase the surface area and therefore
increase the rate of degradation. The degradation product, fumaric acid (FA), was
evaluated by HPLC equipped with a diode array detector. Analysis was carried out
using 97:3 0.02M ammonium hydroxide: methanol as the mobile phase, the pH was
adjusted to 2.35 with phosphoric acid and 0.03M ammonium acetate was added in
order to avoid silonal effects with the column. The mobile phase was set to a flow
rate of 0.25 ml/min. The degradation products of PPF and PBF crosslinked
networks, were separated via a X Select HSS T3 column (35 µm × 100 mm) and
chromatograms were acquired at a UV absorption of 200 nm.
First, to determine the retention time of FA under these conditions (ie. flow
rate and column) a calibration curve was generated by preparing FA standards of 0,
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0.05, 0.15, 0.25, 0.35 and 0.5 mg/ml in 1N NaOH (aq). Once the parameters were
established, the degraded polymer samples were then run under the same HPLC
conditions. Upon acquisition of chromatographs for uncrosslinked and crosslinked
PPF and PBF, the degree of crosslinking for the network was calculated by the
following:
X  =  

Ax
  
A0

Where X represents crosslinking density, Ax is the intensity of the FA peak in the
crosslinked network and A0 is the FA peak intensity in the uncrosslinked polymer.

2.4.4. Sol Fraction and Swelling Ratio Measurements
Solid samples were fabricated by dissolving 3 wt% BAPO/g polymer (PPF or
PBF) in minimal dichloromethane (DCM) followed by solvent removal and placement
in glass molds (diameter = 6mm). Polymers were then subjected to UV curing and
crosslinked cylinders were removed from molds and cut into small discs (6 mm x
0.06-0.08 mm, diameter x thickness) (n = 3). Initial mass (Mi) was recorded and
crosslinked polymer disks were immersed in toluene (~3 ml) for 48 hours. After
soaking, discs were removed and lightly blotted to remove any attached solvent from
the disks surface. The wet mass was measured (Mw). Excess solvent from the
disks was removed in vacuo overnight and reweighed to determine a final or dry
mass (Md). The swell degree was calculated using the following equation:

Swell  =  

(Ms -‐Md )
  
Ms
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The sol fraction, or the fraction of polymer following crosslinking that is not part of
the crosslinked network was calculated via the following equation:

Sol  fraction=  1-‐  

Mi -‐Md
  
Mi

2.5. Sample Preparation for Degradation of Crosslinked Networks
2.5.1. Silane Treatment of Glass Molds
Glass molds (diameter = 6 mm) were placed in a desiccator along with a
beaker containing a few drops of tridecafluoro-1,1,2,2 tetrahydrooctyl)trichlorosilane.
Vacuum (50 Torr) was applied to the desiccator for 30 minutes, followed by closure
of the vacuum valve. The molds were allowed to sit overnight under vacuum.

2.5.2. Sample Fabrication for Degradation Studies
Polymer containing BAPO photoinitiator was prepared by dissolving 3% (w/w)
BAPO/g polymer in a minimal amount of DCM. The solvent was removed in vacuo
prior to filling the freshly silane treated glass molds. Initiator loaded polymer solution
was delivered to the glass molds (diameter = 6mm) via a plastic syringe. The filled
glass vials were subjected to centrifugation (3 minutes at 5000 rpm) in order to
remove any air bubbles and/or defects. The polymer filled cylinders were than
subjected to vacuum desiccation overnight, followed by centrifugation (5 min at 3000
rpm) before photo crosslinking. Polymers (PPF and PBF) were crosslinked using a
UV Fusion ® System, for 15 passes at a belt speed of 15 at 25% power (43.133
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mJ/cm3). After the initial UV exposure, the vials were broken and the samples were
exposed for 30 passes at belt speed of 15 @ 50% power (551.193 mJ/cm3). All
crosslinked samples were cut using a wet saw in order to achieve a height:diameter
of 2:1 (12: 6 mm) (Figure 4.2).

2.6. Accelerated In Vitro Degradation
Sodium hydroxide (0.1N) was used to accelerate the hydrolysis reaction.
Initial height, diameter and mass were recorded for each cylindrical sample prior to
placement in a 20 mL scintillation vial. Accelerating solution, NaOH (0.1N, 10 mL)
was added to each vial and tightly sealed. Vials were placed in an incubator
equipped with shaker plate and maintained at 60°C under gentle agitation (~65 rpm).
At each timepoint, five samples were pulled and wet dimensional measurements
were recorded. Samples were then rinsed thoroughly with dH2O and dried in vacuo
for a minimum of 24 hours to ensure removal of any residual water. Upon drying
samples were dimensionally analyzed for a final time in order to record dry height,
diameter and mass changes. Control samples of PPF underwent the same
procedures.

2.7. Mechanical Testing
Compression testing was performed on the dry cylindrical crosslinked
networks using an Instron 5500R load frame equipped with TestWorks software,
10,000 lb load-cell in accordance with ASTM D695-02 for rigid plastics. Samples
are compressed at 0.1 in/min, up to a strain of 0.5 with a data acquisition rate of 5
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Hz. Stress-strain curves were than exported to Microsoft® Excel and were analyzed
in the linear region (5 – 20% strain) to determine sample modulus.

2.8. Dimensional Analysis
Changes in mass and dimension and water adsorption were calculated for
each time point using the initial mass (Mi), wet mass (Mw) and a dry mass (Md).
Mass loss and water adsorption (uptake) over the duration of the degradation study
by the following equation:

%  Mass  loss=  

(Mi -‐Md )
  x  100
Mi

%  Water  adsorption=  

(Mw -‐Md )
  x  100
Md

Fractional changes in height and diameter were calculated using the following,
where the subscript d indicates dry and i indicates initial conditions:

Fractional  height  change =   

H!
H!

Fractional  diameter  change =   

D!
D!
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2.9. Statistical Analysis
Network characterization and degradation were carried out on un-crosslinked
and crosslinked PPF and PBF networks. Crosslinking density, sol fraction and
degree of swelling determinations were carried out in triplicate (n = 3). Accelerated
degradation determinations were carried out in quintet (n=5), including dimensional
changes ( height, diameter and mass) and compressive moduli. Results were
compared by performing analysis of variance (ANOVA) with post hoc testing (ie.
Tukey HSD) via statistical software (IBM SPSS®).

3. Results and Discussion
3.1. Network Characterization
This study aimed to evaluate the reduction of the fumarate carbon-carbon
double bond (C=C) as a result of crosslinking. This was determined using
differential scanning calorimetry (DSC) and Fourier transfer-infrared spectroscopy
(FT-IR). First, chromatograms of un-crosslinked and crosslinked PPF and PBF were
collected to experimentally determine the Cp values associated with each polymer
(Figure 4.3). The Cp is calculated by evaluating the change in heat flow of a known
polymer mass, this is calculated by integrating the area under the curve. The Cp
values for un-crosslinked PPF and PBF were 41.87 J/g and 3.40 J/g and for the
corresponding crosslinked networks was 6.9 J/g and 0.2 J/g, respectively. The
reduction in Cp values of the crosslinked networks of PPF and PBF is attributed to
the correlation of Cp to degrees of freedom in the polymer. Upon crosslinking of the
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polymer network, fewer double bonds are present and therefore the polymer has
less molecular mobility as compared to the un-crosslinked PPF and PBF samples.20,
21

Crosslinking density was then determined to be 84% (PPF) and 94% (PBF) by

calculating the percent change from the un-crosslinked samples (Table 4.1). This
result provides a general idea of the network structure as indicated by the thermal
changes compared to the un-crosslinked polymeric samples.
Second, FT-IR was used to evaluate the decrease in absorbance of the C=C
bond at ~1645 cm-1. The relative level of crosslinking was inspected by changes in
absorbance due to the C=C stretching of crosslinked PPF and PBF networks as
compared to the un-crosslinked networks (Figure 4.4). Molar absorptivity, or
extinction coefficient (ε) of the un-crosslinked networks was determined to be
41,490 ± 2,099.6 (mol×mm/g)-1 for PPF and 30,170 ± 5,576.0. (mol×mm/g)-1 for PBF
using Beer’s Law. These values were than used to calculate the concentration of
double bonds remaining in PPF and PBF networks relative to the absorbnce of the
fumarate peak (1645 cm-1). The concentration of remaining double bonds in
crosslinked PPF and PBF networks was found to be 4.8 x 10-6 ± 2.4 x 10-7 mol/g
and 6.4 x 10-7 ± 1.3 x 10-7 mol/g, resulting in a crosslinking efficiency of 85 ± 3 and
98 ± 2 % respectively (Table 4.1). Based on these results, the evaluation of
crosslinking density by a thermal characterization (Cp) as well as spectral
characterization (FT-IR), the effect of the fumarate C=C reduction and consumption
due to crosslinking was found to be similar for each network using two different
techniques.

	
  

	
  

	
  

	
   53
	
  

In addition to DSC and FT-IR, In addition to evaluating crosslinking density
via reduction of the double bond after crosslinking, polymer network degradation
products were separated by high performance liquid chromatography (HPLC). The
fumarate-based unsaturated PPF and PBF yield fumaric acid (FA) and the
corresponding diol upon hydrolytic degradation of the ester group. Using the
previously established HPLC technique, established by Timmer et al, the FA
component was quantified for both un-crosslinked and crosslinked PPF and PBF
networks. Verification of the technique was performed by first evaluating the
performance of a FA by establishing a calibration curve using the aforementioned
HPLC conditions (Figure 4.5). Chromatographs of FA standards in 1N NaOH
supplied the retention time of ~11 minutes for FA and the peaks prior to 5 minutes
being attributed to NaOH (Figure 4.5). Upon verification of the HPLC technique,
accelerated PPF and PBF un-crosslinked and crosslinked samples were subjected
to HPLC. The concentration of FA in crosslinked network as compared to uncrosslinked networks was used to determine crosslinking densities for PPF and PBF
were calculated to be 76 ± 3 and 87 ± 1 %, respectively (Table 4.1).
These results, in contrast to the crosslinking densities determined previously
by DSC and FT-IR, are significantly lower. This could be due to the assumption that
degradation conditions would completely degrade the polymers as well as have no
secondary reactions that take place by subjecting the uncrosslinked polymers to
basic conditions. However, the same trend of PBF as compared to PPF is observed
among all three characterization techniques evaluated in this study (Table 4.1).
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In addition to quantifying the reduction in double bonds, network
characterization was evaluated by sol fraction and degree of swelling (Table 4.2).
Sol fraction, polymer chains that are not incorporated into the bulk crosslinked
network, was evaluated by submersion in toluene. The crosslinked PPF and PBF
networks were submerged in toluene, this solvent was chosen as the starting
polymer is soluble and it will slightly swell the solvent versus other solvents such as
dichloromethane (DCM), which is a harsher solvent and has destroyed networks in
previous studies.9 After 48 hours of solvent incubation and removal of excess
solvent in vacuo, the sol fraction was calculated. This data indicates that there was
10 wt% (PPF) and 4 wt% (PBF) of the original polymer network mass that was not
incorporated after crosslinking. Indicating that the PBF network is more crosslinked
compared to the PPF. Following sol fraction analysis, the polymer discs were than
placed in toluene for an addition 24 hrs to ensure all of the non-crosslinked polymer
was removed from the crosslinked polymer by displaying no change in mass
following removal of excess solvent in vacuo. Examination of swelling degree
corroborated that the PBF networks were crosslinked more as compared to the PPF
networks (Table 4.2). This trend was expected, as the swelling of PPF should be
larger due to a less crosslinked network relative to PBF.

3.2. Degradation
3.2.1 Silane Treatment of Glass Vials for Sample Fabrication
The 1 ml glass via molds used as sample fabrication were silane treated prior
to use in order to ease removal of the polymer upon crosslinking. Initial attempts
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without silane treatment left crosslinked polymer samples that would adhere to
randomly to the glass upon cooling after the crosslinking reaction. The adhesion to
the glass mold produced stresses in the crosslinked network, thereby creating
defects in the solid samples. Due to this observation, silane treatment of the glass
vials was instituted as a necessary step for sample fabrication. Surfaces of the
glass mold was modified with a fluorosilane in order for a highly hydrophobic surface
to be presented. This barrier between the glass and polymer allowed for minimal
wetting and adhesion of the polymer to the glass mold providing a more consistent
crosslinked sample. 23

3.2.2. Accelerated Degradation of Poly(Propylene Fumarate) and Poly(Butylene
Fumarate) (PPF and PBF)
3.2.2.1. Mechanical Testing
Compressive properties of PPF and PBF crosslinked networks were
evaluated under accelerated conditions (0.1 N NaOH at 60°C). Samples were
evaluated after removal from basic solution, followed by soaking in water to remove
excess NaOH and finally in vacuo removal of excess water. PPF degradation has
been shown to degrade through bulk degradation25,	
  where the rate of water penetration
is greater than the rate of ester hydrolysis and water enters the entire structure and
chain scission occurs throughout the network.6, 7 As a network undergoes bulk
degradation, the random breaking of the polymer backbone weakens the network,
resulting in a decrease in mechanical properties.
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The initial compressive moduli was calculated to be 207 ± 18 MPa ( t= 0) for
PBF relative to 122 ± 18 MPa ( t= 0) for PPF crosslinked networks (Figure 4.6, left).
Interestingly, after 24 hrs, the PBF crosslinked networks maintain their decreased
moduli, whereas the PPF networks displayed an increase in mechanical properties
throughout the duration of the experiment (Figure 4.6, right). This phenomenon has
been previously reported for crosslinked PPF networks27, 28 and was attributed to
the incubation in elevated temperatures which allow for further crosslinking of
network.29 Perhaps this observation can be supported by the crosslinking efficiency
results for our PPF networks (Table 4.1).

3.2.2.2. Dimensional Analysis
Mass loss is a later indicator of degradation as polymer chains are only able
to leave the network once enough ester bonds have been broken thoughout the
network to release small degradation products. Both PPF and PBF display a similar
trend in weight loss with in the first 24 hrs of incubation, with ~20 % mass loss (g).
However, after 24 hrs, the mass of PBF crosslinked networks starts to decline at a
faster rate compared to PPF. The final mass loss observed after 60 hrs are
presented in Figure 4.7.
In addition to mass loss, sample height and diameter were monitored
thoughout the study and fractional changes were calculated. There was little to no
difference seen in dimension over time for both PPF and PBF crosslinked networks
(Figure 4.8). The lack of dimensional changes indicates that crosslinked PPF and
PBF networks are undergoing bulk erosin.6 Furthermore, these results suggest that
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crosslinked scaffolds upon implantation in vivo would not have significant network
changes in physical structure.
Water absorption was also evaluated, PBF displayed a higher percentage of
water uptake compared to PPF throughout the 60 hr study (Figure 4.9). This
observation supports our hypothesis that the inclusion of the methylene unit
(-CH2) in PBF would allow for increased water ingress over PPF networks
crosslinked in the same manner, as there is a significant increase in PBF as
compared to PPF at each degradation time point.

4. Conclusions
Photo crosslinked poly(propylene fumarate) (PPF) and poly(butylene
fumarate) (PBF) networks were evaluated by calculating double bond reduction
(consumption) due to crosslinking by heat capacity, Cp (DSC) and changes in
absorbance as correlated to concentration of double bonds (FT-IR). In addition, high
performance liquid chromatography (HPLC) was used to evaluate the presence of
fumaric acid (FA) in crosslinked and un-crosslinked networks. In addition, common
crosslinking density techniques were employed to evaluate sol fraction and degree
of network swelling. Crosslinked network performance was was evaluated by both
changes in mechanical properties and mass loss by monitoring compressive moduli
and mass. These results indicate that the inclusion of a methylene unit (-CH2) within
the glycol structure results in a fumarate-based polymer with mechanical properties
suitable for orthopedic applications. Furthermore, the rate of degradation is
increased relative to PPF without sacrificing those mechanical properties.
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Figure 4.1. Schematic illustration of the effect of surface and bulk erosion on
samples as a function of time (left to right). (Adapted from Gopferich, 1996, # 6)
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Figure 4.2. Schematic representing the glass mold filling/crosslinking procedure,
producing crosslinked polymer samples to undergo evaluation via degradation.
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Figure 4.3. DSC thermographs from which heat capacities (Cp) were determined
for uncrosslinked (—PBF and —PPF) and photocrosslinked (- -PBF and - -PPF)
networks (left). Onset temperature of Cp for each crosslinked network is seen at
~100°C (right).
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Figure 4.4. Representative FTIR spectra for uncrosslinked (—PBF and —PPF) and
photocrosslinked (- -PBF and - -PPF) networks in the region of 1600-1800 cm-1. The
fumarate (C=C, double bond) absorption occurs at ~1645 cm-1 (left).
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Figure 4.5. Representative calibration chromatograms of fumaric acid (FA)
standards intensity as a function of retention time in 1N NaOH for the entire run time
(left) and zoom in of peak attributed to FA (right).
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Figure 4.6. Compressive moduli (left) and normalized moduli (right) for PBF (n)
compared to PPF (l) crosslinked networks as a function accelerated degradation
time. Results represent mean ± standard deviation for n = 5.
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Figure 4.7. Percent change in specimen mass of PBF (n) compared to PPF (l) as
a function accelerated degradation time. Results represent mean ± standard
deviation for n = 5.
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Figure 4.8. Fractional change in height (left) and diameter (right) for PBF (n)
compared to PPF (n) as a function accelerated degradation time. Results represent
mean ± standard deviation for n = 5.
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Figure 4.9. Water absorption, or % water uptake for PBF (n) compared to PPF (n)
as a function accelerated degradation time. Results represent mean ± standard
deviation for n = 5.
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Table 4.1. Crosslinking Density of PPF and PBF networks. *Results are represent
mean ± standard deviation for n = 3.
Characterization Method

PPF

PBF

DSC

84%

94%

FT-IR *

85 ± 3%

98 ± 2%

HPLC *

76 ± 3%

87 ± 1%

Table 4.2. Crosslinked PPF and PBF network characterization. Results represent
mean ± standard deviation for n = 3.
PPF

PBF

Sol Fraction

0.1 ± 0.0

0.04 ± 0.0

Swelling Degree

0.05 ± 0.0

0.02 ± 0.00
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Chapter 5: Cytotoxicity Evaluation of Crosslinked Poly(Butylene Fumarate)
Networks and their Osteoconductive Potential
1. Introduction
As the field of tissue engineering continues to evolve, researchers are
working towards unique modifications of existing polymers or creation of novel
polymer systems for biomedical applications.1 Prior to use, all biomaterials must be
tested in cellular environments, both in vitro and in vivo, to evaluate the cellular
response to the material. Initial cell response can be evaluated through in vitro
cytotoxity, a measurement of the materials toxic potential to cells.2, 3 Cytotoxic
potential is measured by the appearance of cell death or inhibition of cell
proliferation.
Recently, we have synthesized the homo and copolymers of poly(butylene
fumarate) (PBF) and poly(butylene fumarate)-co-(butylene maleate) (PBFcBM).4-6
These new fumarate-based polymers are modeled after the biomaterial
poly(propylene fumarate) (PPF), where propylene glycol (PG) is used instead of
butylene glycol (BG). Poly (propylene fumarate) (PPF) crosslinked networks have
undergone cytotoxity studies to evaluate its potential as a good biomaterial.2
Biodegradability of PPF, through hydrolytic cleavage of the ester functionality in the
polymer backbone, results in the generation of fumaric acid and propylene glycol.7
In addition to being biodegradable, an ideal materials degradation products will
easily be expelled from the body without resulting in an inflammatory response.
Both fumaric acid and PG are capable of fulfilling this requirement and will easily be
removed through metabolic pathways (Kreb’s cycle). With this substitution of BG in
place of PG, the degradation products will be fumaric acid and BG. Again, fumaric
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acid will be expelled via the Kreb’s cycle where as BG is likely to be metabolized
primarily in the liver due to the high concentrations of alcohol and aldehyde
dehydrogenase.8 The biocompatibility of BG should also not cause issues as it has
been approved and used as an additive in cosmetics9 and food10, as well as
treatment for ethylene glycol poisoning in dogs.11
In addition to a material for potential orthopedic applications being
cytocompatible, the material must support and allow for the attachment, proliferation,
differentiation and the ability of the cells to lay down extra cellular matrix (ECM) on
the scaffold material.12 This task, like biocompatibility/cytotoxicity, can be screened
in vitro through evaluation of cell-material interactions. To this end, mesenchemyl
stem cells (MSCs) have been utilized in the area of bone tissue engineering (BTE) to
evaluate interactions of cells with the scaffold.13, 14 MSCs, a multipotent selfrenewing stem cell is a progenitor of adipogenic (fat), chondrogenic (heart) and
osteogenic (bone) lineages.15-17 These cells within their native stem cell niche (bone
marrow) are capable of receiving chemical, biological and mechanical stimuli which
allows differentiation of the MSCs. This process of osteogenisis can be mimicked in
vitro by adding supplements to the culture medium.
Osteogenic differentiation of MSCs is induced in vitro by the presence of
dexamethasome (Dex), ascorbic acid (Asc) and β-glycerol phosphate (β-GP). Each
of these supplements serve a specific purpose in differentiation of MSCs to the bone
forming osteoblastic cells, they are: 1) the expression of a mineralized matrix by the
synthetic glucocorticoid Dex, 2) supplying a cofactor for the hydroxylation of proline
and lysine residues in collagen and finally 3) a source of inorganic phosphate in β-
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GP, which is also needed in matrix mineralization and enzymatically hydrolyzed by
alkaline phosphatase (ALP).18
Osteogenesis occurs in stages this is depicted in Figure 5.1 and can be
categorized into 3 stages. First, days 1-4 in culture there is a peak in cells seen with
early cell differentiation from days 5-11 of the protein expression of ALP. Secondly,
early deposition of collagen I provides a matrix for mineral deposition to be
deposited. Lastly, days 14 – 28 result in high expression of osetocalcin and
osteopotin.19
In this chapter we evaluate the cytotoxicity of the newly synthesized PBF, as
described in Chapter 3 from maleic anhydride. In addition evaluation of the new
fumarate-based material is assessed for its osteoconductive potential by osteogenic
differentiation of MSCs in vitro, monitoring ALP expression and mineralization.

2. Materials and Methods
2.1 Chemicals and Reagents
Maleic anhydride (briquettes 99%, MA)	
  1,3-butanediol (Reagent Plus®, 99%,
BD), phenylbis(2,4,6-trimethylbenzoyl)-phosphine oxide (97%, BAPO),
dexamethasome (minimum 98%, Dex), L-ascorbic acid (cell culture tested, Asc),
β−glycerophosphate disodium salt hydrate (BioUltra, β-GP), cetylpyridinium chloride
(USP specked, CPC), alizarin red S (ARS) and sodium phosphate dibasic (BioXtra ≥
99.0%,Na2HPO4) were purchased from Sigma. Tris buffer (10X, Tris) and triton X100 were purchased from EMD Millipore. 2-amino-2-methyl-1-propanol (99%,

	
  

	
  

	
  

	
   67
	
  

2A2M1P) was purchased from Acros.. Silicon vacuum grease was obtained from
Dow Corning. All chemicals were used as received from suppliers.

2.2 Cell Culture
The murine osteoblastic cell line (MC3T3-E1) was purchased from ATCC
(Manassas, VA). Fetal bovine serum (FBS), αMEM,	
  penicillin/streptomycin (10,000
units/ml penicillin; 10,000 units/ml streptomycin, P/S),	
  trypsin/EDTA (0.25% (w/v))
and fungizone (250mcg/ml amphotocin B in saline, 205 mcg/ml sodium
deoxycholate) were purchased from ThermoScientific. Rat bone marrow derived
mesenchemyl stem cells (MSCs), DMEM (GlutaMax® medium), MSC qualified fetal
bovine serum (MSC-FBS), αMEM (GlutaMax® ribnucleosides and
deosyribonucleosides medium), TrypLE™ express disassociation enzyme and
trypan blue (0.4 %) were purchased from LifeTechnologies. Tissue culture
polystyrene (TCPS) 75cm2 Flasks (75-T) and 96 well plates were purchased from
Corning. Non-TCPS 96 well plates were purchased from BD Falcon. LIVE/DEAD®
Viabilty/Cytotoxicity (L/D) kit for mammalian cells was purchased from Invitrogen®.
Cell Titer 96® AQueous One Solution Cell Proliferation Assay (MTS) was purchased
from Promega®. Both assays were used in accordance to manufacturer’s protocol. 	
  

2.3 Equipment
Cells were incubated under standard culturing conditions using a CO2
incubator (NAPCO series, 800 DA, ThermoSci). A sterile environment for tissue
culture was maintained using a class II type A2 biological safety cabinet (Labguard).
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Cell spinning was performed using a Isotemp 110 centrifuge (Fisher). Cell counting
was carried using a hemocytometer (Hyclone®, ThermoSci). Cell imaging was
carried out using a NIKON Eclipse TS100 equipped with camera and Spot imaging
software. Absorbance readings were collected using a plate reader (SpectraMax
M5) and data was processed using Microsoft® Excel. Thin films of polymeric
networks were created using a drawdown machine (Gardco Automatic Drawdown
Machine,Otto).

2.3 Cell Culture
2.3.1 Cell Line: Mouse Osteoblastic Fibroblasts (MC3T3-E1)
A murine osteoblastic cell line, MC3T3-E1 were received from
ATCC®, thawed and established according to manufacturer’s specifications. Cells
were cultured in 75-T tissue cultured polystyrene (TCPS) flask using αMEM
supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v)
penicillin/streptomycin and 1 % (v/v) fungizone at 37°C with 5% CO2 with 95%
relative humidity (RH).
Passaging of MC3T3-E1 (typically 3-5 days) was carried out when cell
coverage of the 75-T flask was at 70-80%. Briefly, medium was aspirated followed
by lifting of the cells under 37°C incubation with 2 ml of 0.25% (w/v) trypsin/EDTA for
3-5 minutes. Fresh medium was added (~5 ml) to the cell/trypsin solution and the
resulting cell suspension was spun via centrifugation at 2000 rpm for 5 minutes.
Upon retrieval of the cell pellet ~2 ml of fresh media was added and the cells were
counted via a hemocytometer. Trypan blue (1:1 v/v) solution was used in order to
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discriminate between live and dead cells. Following counting, a stock solution of
cells was prepared.

2.3.2 Primary Cell: Rat Bone Marrow Derived Mesenchymal Stem Cells (MSC)
Rat (Sprague Dawley) mesenchymal stem cells (MSC) were purchased from
LifeTechnologies thawed, and established according to manufacturer’s
specifications. Cells were cultured at a minimum initial seeding density of 3,000
cells/cm2 in a 75-T TCPS flask in DMEM GlutaMax® medium supplemented with
10% (v/v) MSC qualified fetal bovine serum (MSC-FBS) at 37°C with 5% CO2 and
95% relative humidity (RH). Medium was changed every 2-3 days. Differentiation of
MSCs was carried out in osteoblastic medium (OB) consisting of αMEM GlutaMax®
supplemented with 10% (v/v) MSC-FBS, 10-8 M dexamethasone (Dex), 10 mM
β−glycerophosphate (β−GP) and 50µg/ml ascorbic acid (Asc) at the same culturing
conditions as undifferentiated MSCs.
Cell passaging of MSCs (typically 2-3 days) was carried out when cell
coverage of the 75-T flask was at 70-80%. Briefly, medium was aspirated cells were
incubated at 37°C with 5 ml of TrypLE™ disassociation enzyme for 3-5 minutes.
Fresh medium (~5 ml) was added to the cell/TrypLE™ and the cell suspension was
spun via centrifugation at 1100 rpm for 5 minutes. Upon retrieval of the cell pellet,
~2 ml of fresh media was added and the cells were counted via a hemocytometer.
Trypan blue (1:1 v/v) solution was used in order to discriminate between live and
dead cells. Following counting, a stock solution of cells was prepared.
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2.4. Substrate Preparation
Polymers poly(propylene fumarate) (PPF) and poly(butylene fumarate) were
previously synthesized as previously described. (Chapter 3) Thin films of each
polymer were prepared using a solution of 3wt% BAPO/g of polymer in a minimal
amount of chloroform (CHCl3) was added, followed by remove of CHCl3 in vacuo.
The viscous solution was cast via a drawdown machine using a 18x3 rod, and
allowed to sit for 2-5 minutes. After casting of the polymer (PPF or PBF) the film
was then subjected to UV light (λ = 365nm, UV Fusion®) to crosslink the film (15
passes at belt speed of 10 and 25% lamp, followed by 5 passes at a belt speed of 5
and 50%UV). Upon crosslinking, 6mm discs (thickness = 0.12 mm) were punched
out and collected using a biopsy punch. Samples were then attached to the nonTCPS well plate by adding a dap of grease to the bottom of the well prior to adding
the film to the well.

2.5. Cytotoxicity Extraction Assay of Monomers, PBF and crosslinked PBF
Cytotoxicity is assessed in the form of an extraction assay, where evaluation
is performed in order to assess the cytotoxicity potential of any leachable materials
to be cytotoxic. The starting materials as well as resulting polymer and crosslinked
network (MA, BD, BAPO, grease, PBF and crosslinked PBF) were each placed in
individual wells in a 6 well TCPS well plate. Monomers were incubated at 1
mmol/mL media, while the grease and PBF were incubated at 2 cm2/mL media
under normal cell culture conditions for 24 hours. Prior to performing the extraction
assay, MC3T3-E1 cells were harvested from 75-T flasks using 2 mL trypsin/EDTA
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per flask. Cells were counted using a hemocytometer and a stock solution of cells
was prepared to obtain a seeding density of 8,000 cells/cm2. Cells were seeded in a
96 multiwell TCPS plate. Following 24 hr cell culture in regular medium, medium
was aspirated and replaced with extracted media at 100, 10 and 1 % (v/v) for n = 5
at each dilution (Figure 5.2). Cell viability was tested using LIVE/DEAD®
Viability/Cytotoxicity kit for mammalian cells per the manufacturers’ specifications
and cell images were obtained. The commercially available assay uses calcein AM
and ethidium homodimer-1 to fluorescently stain live and dead cells, respectively.
Calcein AM is cleaved by live cells, producing a cytoplasmic green fluorescence and
ethidium homodimer-1 stains nucleic acids, allowing for those cells with
compromised membranes to be stained red.20

2.6. Cell Attachment
Crosslinked films (PPF, PBF, PPFcPM and PBFcBM) (n=5) were washed with
DPBS (5 ml, 2×) to remove any debris, followed by placement in a 96 non-tissue
culture polystyrene (non-TCPS) well plate adhering the substrates to the well using a
small dob of grease on the underside of the substrate. Cells, MC 3T3-E1, were
cultured using the conditions stated in the cell culture section. Once cells were 8090% confluent, they were lifted using trypsin/EDTA (2ml/75-T flask), counted using a
hemocytometer, and diluted with culture media to obtain a seeding density of 25,000
cells/well. After 24 hrs of culture, attachment and cytocompatibility was evaluated
through the use of brightfield imaging and LIVE/DEAD® Viability/Cytotoxicity kit for
mammalian cells.
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2.7. Osteogenic Differentiation of MSCs
2.7.1. Substrate Seeding with MSCs
After establishing and splitting the rat MSCs cells were counted using a
hemocytometer and diluted with media in order to obtain a seeding density of 1,000
cells/cm2.21 Crosslinked films of PPF and PBF (each formulation had n= 75) were
rinsed (3×) with DPBS to remove any debris, followed by adhering to a non-TCPS
96-well plate (using a dab of grease between the well plate and crosslinked polymer
film). Once films were adhered to the wells, samples were sterilized by exposure to
UV for 30 min, and finally rinsed with DPBS before seeding with MSCs. Cells
underwent normal culturing conditions (37°C, 5% CO2 and 95 % RH) in DMEM
GlutaMax® medium for 24 hours, after which the medium was aspirated and
replaced with osteoblastic (OB) media which was replaced every 2 days for the
duration of the study. Time points which were evaluated in this study were at 2, 4, 7,
11 and 14 days from the start of OB medium conditions (24 hours after seeding). In
addition to the seeded substrates, control plates (minus substrates) of 96-well TCPS
plates were also seeded with MSCs and treated as MSC/substrate plates.

2.7.2 Cell Viability and Proliferation
The colorimetric MTS assay was used to evaluate cell viability and
proliferation. Briefly, 20µl of assay solution is directly added to the 100µl of
cell/medium solution and incubated in the dark at 37°C for 4hrs. Upon completion of
incubation the absorbance of each well was read at 490 nm. The absorbance
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reading is a direct measurement of living cells, as the MTS tetrazolium salt is
converted only to a soluble formazan product by those cells that are viable. Cells
were evaluated after 2, 4, 7, 11 and 14 days in contact with OB medium.

2.7.3. Alkaline Phosphatase (ALP) Activity
The enzyme ALP is a cellular enzyme that can be measured in living cultures
and is expressed early on in osteogenic differentiation.22 The ALP protocol followed
is specific to the Dirk Lab and is a compilation of previous established techniques.23,
24

Briefly, the culture medium was aspirated and the wells were carefully washed 3×

with 100 µl of DPBS. Cells were than lysed by adding 100ul of 1% (v/v) Triton X-100
to each well followed by incubation for 60 min while on ice. Upon completion of
lysis, 30 µl of the lysate was transfer to new wells of a TCPS 96-well plate. To this
lysate was added 50 µl of 2-amino-2methyl-1-propanol (2A2M1P)	
  and 50 µl of 40mM
4-nitophenol phosphate hexahydrate (4-NPP) substrate was added. Absorbance
readings were measured at 405 nm at 15, 30 and 60 minutes during incubation at
room temperature (RT) and this reading is a resultant of the ability of ALP to convert
the substrate (4-NPP) to p-nitrophenol (p-NP). A standard curve is also constructed
using p-NP serial dilution. Samples were evaluated after 2, 4, 7 and 11 days in
contact with OB medium.

2.7.4. Calcium Mineralization
The anthriquinone dye alizarin red S (ARS), is used to evaluate matrix
deposited calcium mineral content by forming a complex via chelation. Mineral
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deposition was evaluated and quantified following the protocol described by Gregory
et al.25 Briefly, culture medium was aspirated, wells were rinsed 3× with DPBS
followed by fixation using ice cold 70% (v/v) ethanol (EtOH) for 1 hour. After fixation,
30 µl of 40 mM ARS staining solution (pH 4.1-4.2) was added to each well and
incubated for a minimum of 30 minutes in the dark at room temperature (RT). Upon
completion the ARS solution was aspirated and the wells were rinsed 5× with dH20
and 3× with PBS in order to ensure removal of non-specific ARS stain. Samples
were briefly visualized under brightfield and than underwent a dye extraction in order
to quantify the amount of staining and therefore calcium content. ARS was
extracted from the cultures through the addition of 100µl 10% (w/v) cetylpyridinium
chloride (CPC) in 10mM Na2HPO4 buffer for 1 hour at RT. Upon completion of
incubation with CPC the solution was moved to a new TCPS plate and the
absorbance was read at 550 nm. Samples were evaluated after 4, 7, 11 and 14
days in contact with OB medium.

3. Results and Discussion
3.1. Evaluation of Cytotoxicity
The potential utility of crosslinked PBF films as a tissue engineering scaffold
material was further evaluated using the extraction cytotoxicity assay of the
monomers, the polymer itself, and crosslinked polymer. These extraction assays are
used to assess whether there were any leachable products that would be toxic to
surrounding cells. Serial dilutions of extraction medium, or medium which had been
exposed to either maleic anhydride, 1,3-butylene glycol (BG), PBF and crosslinked
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PBF solid substrates (MA, BG, BAPO, PBF and crosslinked PBF) were used to carry
out this assay.
Extracted media was mixed with culture media at levels of 100, 10, 1 and 0 µl
(v/v) followed by incubation at cell culture conditions for 24 hours as outlined by
Timmer et al.2 Cells exposed to high concentrations of 1,3-butane diol (BD)
appeared to have altered morphology of the cells when exposed to extraction media.
This is likely a result that the BD was miscible with the extraction media and as a
result the MC 3T3-E1 cells were exposed very high concentrations of BD over the
entire 24 hour incubation period, unlike the other “extracted” media incubations. To
further assess cell viability a LIVE/DEAD ® Viability/Cytotoxicity kit for mammalian
cells was performed. All 24 hour cell incubations with the extracted media rendered
only viable cells, indicated by green, and no non-viable cells were observed, stained
red (Figure 5.3). Although MC3T3-E1 cells exposed to 100 µl of extracted BD media
had a rounded morphology, upon fluorescent staining of the cells there were no
dead cells observed within the sample (lack of red fluorescence) (Figure 5.3). The
fewer number of cells observed in this extraction condition (exposure to BD) and
lack of dead cells may indicated that the dead cells were washed away prior to
staining.
The results indicate that there is nothing cytotoxic leaching out of the PBF,
the crosslinked PBF or BD that is toxic to the cells. Cells were evaluated under
brightfield and fluorescent imaging to assess cell morphology and spreading, as they
are an indicator of cellular function on a surface. Comparison of cultured cells
incubated with monomers and polymers to those which were cultured with 0 µl
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extracted media show that the cell line MC-3T3 behave as they do on TCPS under
normal culturing conditions (Figure 5.2).

3.2. Attachment of MC3T3-E1 to Crosslinked Polymer Substrates
In addition to the extraction assay with MC3T3-E1, attachment on crosslinked
solid PBF films was examined. The murine cell line was seeded on the PBF films at
a seeding density of 25,000 cells/well and cultured at cell culture conditions for 24
hours. Cells seeded on PBF substrates were than imaged using the fluorescencebased LIVE/DEAD® assay according to manufacturer’s protocol in order to observe
the cell viability, where viability is visualized based on membrane integrity. PBF
synthesized from MA allow for cellular attachment (Figure 5.4). The crosslinked
PBF films fluoresce due to incubation with the dyes used in the LIVE/DEAD® kit and
create a background fluorescence, this is seen in the images taken with the Nikon
TS100.

3.3. Attachment, Viability and Osteogenic Differentiation of MSCs
3.3.1. Attachment and Viability
Prior to the start of the 2 week study, seeding efficiency of MSCs on the
crosslinked polymeric network of PPF and PBF was evaluated. Cells were seeded
at 1,000 cells/ cm2 followed by incubation at 37°C, 5% CO2 and 95% RH for 24
hours. After 24 hrs, cells were fixed via 1% (v/v) formaldehyde and stained with 4’,6diamidino-2-phenylindole dihydrochloride (DAPI), a nuclear stain, to visualize cell
location (Figure 5.5). Cell attachment to TCPS compared to crosslinked PPF and
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PBF films is greater by ~1.5-2× higher as indicated in cell number at Day 2 (Figure
5.5). However each seeding environment, including PPF and PBF crosslinked
films, provide a suitable environment for the anchorage-dependent MSC cells.
Cell viability, as assessed by the colormetric bioreduction of MTS tetrazolium
salt to formazan, shows a similar trend across all samples. Figure 5.6 shows a peak
in cell number at day 4, followed by a decline at day 7 – 14. A possible reason for
this could be due to the inclusion of 10-8 M dexamethasome (Dex), although this
synthetic glucocorticoid is required in osteoblastic media (OB) to promote
mineralization, it has also been seen to have an apoptotic effects on MSC cultures.26
In addition, contact inhibition has been reported to suppress cell proliferation and is
surface area dependent.27 This may be the cause of our decrease at seen at Day 7
following the rapid proliferation from Day 2 to Day 4 (Figure 5.6).

3.3.1. Evaluation of Alkaline Phosphatase (ALP) Activity
The enzyme-catalyzed reaction operates by removing a phosphate from the
substrate (4-nitophenol phosphate hexahydrate, 4-NPP), generating free phosphate
(Pi) and the chromophore p-nitrophenol (p-NP) (Figure 5.7). The yellow colored pNP has a maximum absorption at 405 nm and Beer’s Law can be used to calculate
the ALP concentration:
ALP  Activity=  

A60 -‐A0   (1000)  Vrxn
Trxn   (ε)(l)  Vsample

The modified equation, is used to calculate the concentration of enzyme (ALP) over
the 60 minute kinetic study where the absorbance (A) is equal to the A at t = 60 min
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minus A at t = 0 min, the reaction volume (Vrxn) is 130 µl (substrate + lysate + buffer),
the sample volume (Vsample) is 30 µl (lysate), the extinction coefficient (e) at 405 nm
for p-NP is 18.5 mM-1cm-1,28 the path length (l) is 1 cm and the reaction time (T) is 60
minutes. This equation provides ALP activity in µmol/L*min, or IU/L and can than be
divided by the cell number obtained via MTS to obtain activity of ALP in IU/L per cell.
As seen in Figure 5.7, the ALP activity in MSCs with osteoblastic media (OB)
peak at Day 7 and than decreases by Day 11. This is in contrast to cells that are
cultured on PPF and PBF, were a significant increase over the control is seen on
Day 2, peaking earlier than those MSCs cultured on TCPS, followed by continuous
decline observed from Day 4 – 11 (Figure 5.7). Previous studies indicate that initial
osteoprogenitor cell proliferation is rapid, leading to an increased production of
extracellular matrix (ECM), followed by a decrease in proliferation, as we observed
in these results (Figure 5.5) as well as an upregulation of ALP expression.27, 29
There are two controls of this assay, MSCs seeded on the TCPS 96-well as well as
the MSCs seeded on PPF crosslinked films. Both PPF and PBF show a similar
trend and expression of ALP, where there is a significant difference seen on the
TCPS controls. It has previously been reported that the cell density has an effect on
ALP expression27, with a lower density displaying an enhanced expression. This
could account for the observation of PPF and PBF having an increased ALP
expression over TCPS as the initial cell attachment at Day 2 was ~20,000 and
~35,000 to 40,000, respectively (Figure 5.7).
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3.3.1. Evaluation of Matrix Mineralization via Alizarin Red S (ARS)
Dexamethacsome (Dex) is used in osteoblastic media, as it is necessary to
promote mineralization. Prior research has demonstrated that ALP expression will
still be observed, but mineralization will not occur unless the media is supplemented
with the synthetic glucocorticoid.18 The ARS staining is extremely versatile in that it
can be observed optically (qualitative) as well as extracted using cetylpyridinium
chloride (CPC) and the absorbance read it 550 nm (quantitative). The ARS salt
forms a complex through chelation with calcium that has been deposited as a result
of osteogenic differentiation.30
Brightfield images demonstrate significant matrix mineralization as seen by
red staining seen in representative images at Day 11 (Figure 5.8). The calcium
extracted by CPC per well is calculated and is reported as mg/well (Figure 5.9). The
amount of matrix deposition on crosslinked PBF is similar to the control of
crosslinked PPF, whereas both PPF and PBF are significantly higher than the matrix
deposition on in the control wells of TCPS. The increase in matrix deposition on
PPF and PBF over the control could be attributed to the increased proliferation seen
in PPF and PBF samples (Figure 5.5 and 5.7) and the possible increase in ECM in
these samples versus the control TCPS sample.

4. Conclusions
In this chapter we present the cellular response of the novel polymer
poly(butylene fumarate) (PBF) as synthesized in Chapter 3. The cytotoxic potential
was evaluated via a solution based extraction method (non-direct contact) and it was
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shown that there were no leachable products that could provide potential cytotoxic
effects. In addition to the attachment, proliferation and viability of the preosteoblastic murine cell line MC3T3-E1, bone marrow derived mesenchemyl stem
cells (MSCs) were used to determine the osteoconductive (supporting bone
formation) potential of PBF compared to the widely explored poly(propylene
fumarate) (PPF). The results of this study reveal that PBF behaves similarly to PPF
and in vitro culture conditions indicate that the new biomaterial will support
attachment as well as serve as an osteoconductive platform for the use in bone
tissue engineering applications.
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Figure 5.1. Schematic illustration of mesenchemyl (MSCs) undergoing osteogenic
differentiation and the early signal (ALP) and later (osteocalcin and osteopotin)
enzymes.

Figure 5.2. Schematic representing cytotoxicity protocol. Each of the monomers,
polymers and crosslinked polymers were incubated in media under normal cell
culture conditions. After 24 hrs, the media (extracted media) was removed and
saved for later use. In parallel, MC3T3-E1 cells were seeded onto TCPS. At ~80 %
confluence the cell culture media was removed and replaced with varying
concentrations of the extracted media (100,10 and 0%).

	
  

	
  
	
  

82

Figure 5.3. Viability assessment of MC3T3-E1 cells with extracted media post
incubation imaged through the use of Epifluorescence (Invitrogen LIVE/DEAD®)
where green represents viable cells and red represents dead cells, the image has
been false colored to represent this. 1A-C) crosslinked PBF solid substrates, 100µl,
10µl and 1µl (respectively) 2A-C)PBF polymer, 100µl, 10µl and 1µl (respectively)
and 3A-C) butanediol at 100µl, 10µl and 1µl (respectively). All scale bars are
100mm.
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24 hrs

3 Days

5 days

Figure 5.4. MC3T3-E1 seeded on crosslinked solid PBF thin films, analysis
performed by LIVE/DEAD® at 24 hrs, 3 and 5 days (left to right). Where green
represents viable cells and red represents dead cells, the image has been false
colored to represent this. Scale bar represents 100µm.

Figure 5.5. MSCs seeded on TCPS (left) and polymeric substrate (right) and
incubated in culture for 24hrs, followed by staining with the nuclear stain DAPI to
determine location. Cells are false colored blue and the scale bar is 100um.
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Figure 5.6. Cell viability as measured by the conversion of MTS tetrazolium to the
soluble formazan product. The quantity of formazan is measured by the absorbance
at 490 nm and is directly proportional to the living cells in culture.	
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Figure 5.7. The enzymatic (ALP) driven assay removes a phosphate from the
substrate 4-nitophenol phosphate hexahydrate (4-NNP, 2) to produce p-nitrophenol
(p-NP,1) (Top scheme). The absorbance of chromophore p-NP at 405nm over a
period of 60 minutes can be used to generate the ALP activity (bottom).
	
  
	
  
	
  

	
  

	
  
	
  

86

	
  
	
  
Figure 5.8. Representative brightfield images of ARS stained cultures from left to
right, MSCs on TCPS, crosslinked PPF and crosslinked PBF substrates (pictured
Day 11). Images at 20X.
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Figure 5.9. CPC extraction of ARS after briefly imaging is used to calculate matrix
deposited calcium in mg per well.
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Chapter 6. Method Development for Fabricating 3D Crosslinked Polymer
Networks via Electrospining and Projection MicroStereolithography
1. Introduction
An important component of the tissue engineering (TE) paradigm lies in the
construction and design of the scaffold. The scaffold serves as a 3D template for
cell attachment, migration and proliferation as well as tissue formation.1, 2 To be
successful, a TE scaffold must possess these basic properties: 1) it must be
biocompatible/biodegradable, 2) display degradation products which can easily be
expelled from the body, 3) contain high porosity, 4) be comprised of interconnected
pores, 5) display a microstructure to mimic the micro-environment, and finally 6)
have suitable mechanical properties for the tissue being repaired/regenerated.3, 4
Many processing techniques have been explored in for many different applications in
the field of TE. In addition to the aforementioned minimum criteria of a TE scaffold,
bone TE (BTE) applications require the scaffold to have a porosity ≥ 90%, display
pore sizes of 200-400µm and have mechanical properties similar to the bone that is
being repairied/regenerated (trabecular/cancellous and cortical bone).4-8
Currently, the only polymer system which meets the mechanical requirement
is the fumarate-based unsaturated linear polyester poly(propylene fumarate) (PPF),
poly(butylene fumarate) (PBF) and their copolymers, which have low glass transition
(Tg) temperatures an can be crosslinked thermally or photochemically through the
carbon-carbon double bone in the polymer backbone.9 These material properties
allows for various fabrication techniques to be implemented, those which are
preformed prior to implantation or as an injectable system to be crosslinked in situ.10
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Several techniques have been employed to fabricate 3D scaffolds of

crosslinked PPF for tissue engineering applications including porogen or solvent
leeching8, 11, freeze-drying12, poly HIPEs13 and multiple stereolithography.14-17 18
However, this chapter focuses on developing methods to produce 3D scaffolds of
fumarate-based polymers that have not had success to date. These two methods
are electrospinning and projection micro-stereolithography (PµSL).
Electrospinning, first introduced as early as 193419 regained popularity in the
mid 90s.20 In contrast to dry or melt spinning, electrospinning uses electrostatic
forces to stretch a solution as it solidifies, allowing for continuous nano to micron
sized films to be fabricated. Currently there are two standard electrospinning
setups, vertical or horizontally fed, that consist of 4 major components.21 As seen in
Figure 6.1, the standard or generic setup, regardless of orientation, includes: 1) a
syringe pump (to deliver the solution), 2) a spinneret (nozzle or needle where
solution erupts from), 3) a DC high voltage source (to allow for solution charging)
and 4) a grounded collection plate (for deposition of fibers). Many research groups
have looked to alter the standard electrospinning set up to produce non-woven
highly porous mats for use in TE applications. The resulting fiber size scale provides
a scaffold that mimics that of the native extracellular matrix (ECM). Although
electrospinning offers a very versatile and inexpensive fabrication technique for
creating high surface area to volume scaffolds, there are current limitations and
drawbacks that are associated with the technique. The generation rate of
electrospun mats compared to the industrial fiber spinning technique speed of
production is much less at ~30 m/min compared to 200-1500 m/min.22 In addition, a
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caveat to this system is that solid polymers are needed to create continuous solid
fiber deposition. A few techniques to spin low glass transition (Tg) polymers have
been developed and require a carrier polymer or a specialized spinneret to produce
core-sheath fibers (low viscosity and/or liquid polymers encased by a sheath).
Stereolithography, first termed by Hull in 198623, is a general term used to
describe printing of layers successively in order to render a three dimensional
polymer structure with the assistance of a computer aided design (CAD). Many
common terms used to describe this process of rapid prototyping (RP) have been
coined, including three dimensional (3D) printing.

The RP technique can generate

complex 3D structures with finely controlled attributes (size, shape porosity and pore
size), however the versatility comes at a cost. An alternative form of 3D printing with
the ability to rapidly make micron sized features from photo-curable polymers that
has recently been identified is projection micro-stereolithography (PµSL).24 This
technique uses the available UV light from a commercial LCD or DLP projector25 to
activate a highly effective photoinitiator. The printing can be repeated repeatedly
when combined with a z-stage to create 3D structures. The cost of this setup is
much less than the tradition $100-500K price tag associated with other RP
techniques.
In this chapter we have developed methods in order to use the fabrication
techniques of electrospinning and PµSL to created scaffold of fumarate-based
polymers. Synthesis of low molecular weight oligomers from diethyl fumarate (DEF)
and propylene glycol (PG) or glycerol have provided less viscous starting materials
over the traditionally synthesized fumarate-based materials. Thereby overcoming
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the limitation of PµSL and being able to pattern these fumarate-based oligomers in
combination with the photoinitiator phenylbis(2,4,6-trimethylbenzoyl)-phosphine
oxide (BAPO). Although electrospinning is a simple technique producing nanometer
to micrometer diameter fibers, there are many variables which effect the resulting
fibers.26 However, traditionally synthesized fumarate-based materials with low Tg’s
have not seen success in spinning. Previously low Tg materials such as
polybutadiene and acrylic copolymers have been spun through the us of a carrier
polymer or post UV crosslinking after spinning.27, 28 Our technique uses a one-step
in-situ crosslinking of fumarate-based polymers and copolymers with BAPO, by
including a UV lamp in the generic electrospinning setup.

2. Materials and Methods
2.1. Chemicals and Reagents
Propylene glycol (ReagentPlus®, 99% PG), glycerol( ≥ 99%) and
phenylbis(2,4,6-trimethylbenzoyl)-phosphine oxide (BAPO) were purchased from
Aldrich. Diethyl fumarate (98%, DEF) and p-toluensulfonic acid (TsOH) were
purchased from Acros Organics. All chemicals were used as received.

2.2 Equipment
Modified electrospining setup, consisting of syringe pump (KD scientific,
model 100s), high voltage supply (Glassman High Voltage, Series EL), stainless
steel blunt tip needles (SmallParts, SSB), grounded collection plate (Cu fitted with Al
foil) and a hand held UV source (UVP, Blak-Ray longwave ultraviolet lamp, model
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B100AP) was constructed in house. A modified projection microstereolithography
(PµSL) setup was designed, consisting of a DLP Projector (Acer Model DSV008), a
converging lens (Edmund Optics), motorized XY stage and 2 computers (Dell).
Scanning electron microscopy (SEM) was carried out using a Zeiss Supera 55VP
and a FEI DB235. Optical images of fabricated scaffolds were captured using an
OmniScope.

2.3. Synthesis of Low Molecular Weight Polymers
Propylene glycol (PG) or glycerol, diethyl fumarate (DEF) (2 or 3 equivalents,
respectively) and p-toluensulfonic acid were added to a 100 mL round bottom flask
equipped with a stir bar and distillation head. The reaction mixture was heated to
250°C with stirring until the distillate was collected. Upon completion of the distillate
collection the reaction was allowed to come to RT.

2.4. Polymer Processing Techniques
2.4.1. Electrospinning
2.4.1.1. General Procedure
All polymer solutions were delivered at a constant rate via a syringe pump
through a syringe fitted with a stainless steel blunt tip needle. The needle was
charged through a high voltage supply, and the resulting polymer fibers were
collected on a grounded target (6 x 6 in). A UV source (λ =365 nm) was used to
crosslink the polymer in situ (Figure 6.2).
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2.4.1.2. Electrospining of Poly(Propylene Fumarate) (PPF) and Poly(Butylene
Fumarate) PBF
A 2-mL plastic syringe [inner diameter (ID) = 4.64mm] equipped with a 20
gauge (g) x 1.5 in. stainless steel blunt tip needle was used to deliver solutions of
polymer dissolved in chloroform (40, 50, and 60 wt %) at a volumetric flow rate of 0.2
mL/hr and a voltage difference of 1 kV/cm from needle tip to collection plate.

2.4.2. Projection MicroStereolithography (PµSL)
2.4.2.1. General Procedure
The PµSL apparatus is comprised of 1) a computer containing the
corresponding PowerPoint® slide of black and white images to serve as the “mask”
for printing the specified geometries, 2) a DLP projector, 3) a converging lens with
15 cm focal distance and finally 4) a stage which a silicon chip is placed to serve as
a substrate to print the structure on to (Figure 6.3).

2.4.2.2. Patterning of LMW Polymers via PmSL
The initiator (phenylbis(2,4,6-trimethylbenzoyl)-phosphine oxide (BAPO)) was
dissolved into the liquid monomer (3 wt%). The polymer solution was placed in a
150-mL beaker and the stainless steel platform was lowered into the solution. A
series of black and white images were created in PowerPoint®, this creates the
“mask” to use for patterning (Figure 6.4). Upon completion of the first crosslinked
layer, a stepper controls lowered the newly formed polymer structure into a beaker
to expose a new uncrosslinked polymer layer. With successive exposures, a 3D
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structure was produced. The structure was than removed from the stainless steel
stage and rinsed with water, followed by continued crosslinking via exposure to a UV
source (λ=356 nm).

3. Results and Discussion
3.1. Electrospinning of Low Tg Polymers
Previously, PPF has been fabricated into highly porous structures with large
surface to volume ratios by the Minkos and Yazemski groups by sovent casting/salt
leaching and high internal phase emulsion (HIPEs).29 Here, we present the
fabrication of high surface area to volume scaffold fabricated through the established
electrospinning technique. Electrospinning is also a very favorable and attractive
technique for fabricating scaffolds for TE applications as it produces a network of
fibers that mimic the biologically relevant extracellular matrix (ECM) environment in
vivo. Traditionally low Tg as well as low viscosity polymers have been spun through
the use of a carrier polymer30-32 and the use of a coaxial needle to incorporate the
“hard to spin” material as the core in a core/sheath design.33, 34
Initial attempts to electrospin PPFcPM were performed by making
polymer/chloroform (CHCl3) solutions of 40, 50 and 60 wt% in order to determine
what concentration was needed in order to spin continuous fibers at 1kV/cm.
Regardless of the polymer solution spun, fibrous mats were not produced when the
low glass transition (Tg) polymer was spun. Instead there was a polymer selfcalendaring effect that was observed (Figure6.5). Attempts to reduce the selfcalendaring effect were seen in reduction of the flow rate from 0.5 ml/hr to 0.1 ml/hr,
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however the polymers flow at room temperature (RT) due to the low Tg still was
observed via scanning electron microscopy (SEM) still revealed self-calendaring.
Final attempts to produce a 3D fibrous network that did not self-calendar
made use of the fact that the polymer can be crosslinked with the use of a
photoinitiator. However, pre-crosslinking the polymer initiator solution prior to
spinning was not possible as it would no longer be soluble in solvent and therefore
could not be spun. PPF has previously been crosslinked using acyl phosphine
oxides as the photoinitiators, as they are known to undergo a rapid alpha cleavage.
Either benzyl or BAPO were incorporated at 3 wt% (g/polymer) into the PPFcPM at
the 40, 50 and 60 wt% polymer/CHCl3 solution. Both solutions (benzyl/PPFcPM or
BAPO/PPFcPM) were spun using the same aforementioned parameters and
elctrospinning set up, with the addition of a hand held UV lamp (l= 365nm).
Previously electrospun mats have been crosslinked via a post processing step,
collection of fibers is done followed by crosslinking.28 In contrast, a UV source
allowed for crosslinking in situ due to the location of the lamp as the fibers were
being spun as well as a post 15 min exposure after fiber collection.
The benzyl/PPFcPM solution still produced self-calendaring fibers,
presumably this was due to the generation of to few radicals being produced during
fiber formation. In contrast, the BAPO/PPFcPM solution was able to form a fibrous
mat. Although a mat was formed, after 0.1 ml was delivered the crosslinked polymer
formed pillars (Figure 6.6). It was determined that the pillar formation was a result of
increased viscosity due to partial crosslinking of the spinning solution as a result of
the UV light being reflected off the aluminum foil on the collection pate back to the
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syringe. To combat the problem of increasing solution viscosity, the syringe was
shielded and in turn a non-calendared crosslinked PPFcPM mat was produced free
of pillars (Figure 6.7 ).Using ImageJ®, 30 random fibers in the SEM image were
measured and averaged to determine the average fiber size to be 6.94 ± 3.64 µm.
Upon modifying the general electrospinning setup, with the addition of an in
situ crosslinking capability, it was extended to spinning of PBF and PBFcBM.
Briefly, the 3wt% BAPO/ g polymer in a 75 wt% CHCl3 solution was spun using the
same parameters as the PPFcPM mat production (0.1 ml/hr and 1kV/cm). Again,
the butylene fumarate-based polymer of PBF produced a crosslinked porous mat
with an average fiber size of 1.08 ± 1.1 um (Figure 6.8).

3.1. Patterning via PµSL
3.1.1. Synthesis
Previously synthesized fumarate-based polymers, poly(butylene fumarate)
(PBF), poly(butylene fumarate)-co-(butylene maleate) (PBFcBM) as well as those
from propylene glycol (PPF and PPFcPM) were synthesized from the ring opening
polymerization (ROP) of maleic anhydride (MA), detailed in Chapter 3. These
polymers were used to carry out the electrospinning experiments discussed here in,
however the viscosity advantage that is desired in electrospinning is not favorable
for carrying out projection microstereolithography (PµSL). Therefore, to overcome
this, short chain fumarate-based monomers were synthesized by an acid catalyzed
condensation reaction from propylene glycol and diethyl fumarate (DEF) (Scheme
6.1 A) and glycerol and DEF (Scheme 6.1 B). Both monomers were synthesized in
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high yields.

3.1.2. Patterning of Fumarate-Based Monomers via PmSL
Prior to patterning with PµSL, solutions of monomer and BAPO were
combined in order to determine the feasibility and utility for use and the ability to be
patterned with PµSL using the BAPO initiator system. Here success was seen if the
monomer/BAPO solution could be crosslinked (λ = 365 nm) in a reasonable time (≤
5 minutes).

Upon verification that the newly synthesized monomers would be

suitable, solutions of BAPO/ monomer were stirred until all of the BAPO was in
solution. Patterning was accomplished using PµSL, however with slight
modifications to the PµSL setup described originally by Fang et al24 was altered.
Specifically, the 45-degree mirror was removed in order to remove trapezoidal
distortions seen from the projector and enable larger areas to be projected directly
into the solution. The differences in the PµSL systems can be seen in Figure 6.3,
but the basic components of the apparatus are the same and is comprised of
computer to display the PowerPoint slides, which served as exposure masks, an LCD
data projector, magnifying glass (3×), beaker with photo-activated monomer solution
and a z-stage with additional computer/controls.
The goal to using these fumarate-based monomers with the inexpensive
PµSL technique is to produce 3D scaffolds for tissue engineering (TE) applications.
Initial 3D structures were created using PowerPoint slides with a regular array of
circles. After the first layer was printed, the array was off-set by half a period and
reprinted. Repeating this process resulted in a 3D structure with interconnected
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pores. The monomer/initiator solution was crosslinked for 90 seconds with each slice
projection, and the stage was lowered by 50 µm after completed layer exposure. The
3D structure was removed from the stainless steel stage and rinsed with water. UV
flood exposure continued to ensure the 3D structure was fully crosslinked. The
structure was than evaluated via optical microscopy. The optical images were
analyzed with the NIH ImageJ® software to determine the pore size of ~960 ± 1 µm
(Figure 6.4).
4. Conclusions
Two fabrication techniques, electrospinning and projection
microstereolithography (PµSL), have been utilized to produce random fibrous porous
mats and 3D porous structures, respectively. Two new fumarate-based monomers
were synthesized via the reaction of excess diethyl fumarate (DEF) with either 1,2propylene glycol or glycerol. These monomers were of sufficiently low viscosity that
they enabled easy patterning via a modified PµSL apparatus. Compared to other
printing techniques, the PµSL approach offers an inexpensive, mask-less system for
printing any low viscosity monomer or oligomer that can be polymerized or
crosslinked via a photoinitiator.
Electrospinning of fumarate-based polymers, PPF and PBF, containing a
highly active photoinitiator (BAPO) produced nano- and micro fibrous mats with in
situ UV crosslinking. The technique should be applicable to all polymers with a Tg
lower than room temperature, containing a photo crosslinkable functional group.
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Scheme 6.1. Synthesis of acid catalyzed condensation reaction to produce
fumarate-based monomers, from A) propylene glycol (2) and DEF (1) and B)
glycerol (3) and DEF.
OH

O
OH

A

+

O

O
O

2

O

1

Catalyst

O

250°C

O
O

OH

3

O

O

OH

B

O
O

O

HO

O
O

+

O

O
O

Catalyst
250°C

O

O
O

O
O

O

O
O

O
O

	
  

	
  

99

A

B

Syringe Pump
Stand
Grounded Plate

High Voltage Source

	
  

Figure 6.1. Schematic illustration of the two generic electrospinning setups,
horizontally fed (A) and vertically fed (B). Both setups consists of a 1) syringe
pump, 2) spinneret, 3) DC high voltage source and 4) copper grounded collection
plate.

!"#$%&'()#

$5'+2,)#4&67#
1'%&23)3#4.0/)#
*+,-#"%./0,)#$%&'()##

Figure 6.2. Schematic illustration of our in house modified electrospinning setup.
Addition of a UV source allows for in situ crosslinking of a photoinitiator loaded
polymer solution.
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Figure 6.3. Schematic of projection microstereolithography (PµSL) comprised of a
1) computer to display Powerpoint® images (serving as the mask), 2) DLP projector,
3) converging lens, 4) 45 degree mirror (reflect image into crosslinking solution), 5)
staging device and 6) beaker containing crosslinking solution (A). (Muskin, 2010,
#24) The modified setup has removed the mirror, by changing orientation in printing
and moving to an automated staging device (B).
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A

B

Figure 6.4. Masks (series of black and white images) created in PowerPoint® to
create a crosslinked 3D structure (A). Porous fumarate-based PmSL printed
substrate (B, left) and corresponding optical image (B, right). Scale bar 1 mm.

A

B

Figure 6.5. Effect of polymer deposition (time) on collection plate during
electrospinning, as more fibers are deposited a self-calendaring effect is observed.
This is visualized in the resulting SEM images A (less dense) and B (more dense).
Scale bar is 20 µm.
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Top View

Side View

Figure 6.6. Pillar formation observed as a result of UV light reflecting back to the
syringe, effecting the viscosity of the solution overtime and thereby depositing
polymer on the same area of the collection plate throughout the collection period.

Figure 6.7. As spun electrospun mat (left) and accompanying SEM image (right) of
the fiber composition seen in left hand image. Scale bar is 100 µm.
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Figure 6.8. As spun PBF mats, areas of less dense fiber collection are seen around
the perimeter (left) and the middle of the mat (right) displays an area of dense fiber
collection. Scale bar is 10 and 20 µm (left to right).
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Chapter 7.
Part I.

Potential Neural Interface Material Printed via Projection MicroStereoLithography

Part II.

Printed Poly(Dimethyl Siloxane) Substrates with Controlled Pore Size:
Studying Flap Revascularization in and Ischemic Mouse Model
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Part I. Potential Neural Interface Material Printed via Projection MicroStereoLithography

1. Introduction
In 1995 it was reported that at least 50,000 nerve repair procedures were
preformed in the United States (US) and in 2002 that number was 250,000.1, 2
These reported values only include those peripheral (PN) injuries which can be
repaired and does account for PN injuries that are beyond repair using current
clinical procedures and requires amputation of the limb. Unfortunately, the number
of non repairable PN injuries is much higher, with about 1.7 million people in the US
reported to be living with limb loss.3 The current treatment for limb loss is to supply
the patient with a static limb, which can decrease an individuals motor or sensory
perception.4
The clinical need is driving the movement from a non static limb to a
neuroprosthetis, or limb which interfaces with the patients nervous system. Many
advancements have recently occurred in robotics5, which has now shifted the
research focus to lie on coupling the prosthesis with the nervous system through
peripheral nerve interfaces (PNI).3, 6 Neural interface devices operate at the
intersection of the peripheral nervous system and an external system. These
interfaces can be used to monitor nerve signals or provide inputs to allow amputees
the ability to control prosthetic devices the same way they would control parts of
their own body, by using direct neural signals.
Several approaches to developing PNIs, which are aimed to control prosthetic
devices as well as augment nerve regeneration, have been evaluated in a research
setting and can be categorized into 3 basic categories, 1) cuff 2) penetrating and 3)
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regenerative.6 Cuff electrodes are comprised of an insulating sleeve around the
nerve, electrically simulating the superficial fascicles of the nerve. Therefore the
lack of contact and spatial selectivity is a limitation of the cuff design.6, 7 The lack of
contact seen with the cuff design is dealt with in the penetrating electrode design,
where electrodes are pushed into the nerve and the “needle like” design can have
many contacting electrodes built in.8 However, like the cuff electrode there are
drawbacks, the material selection for penetrating electrodes has been limited to high
modulus materials such as silicon.6, 9, 10 Lastly, regenerative or sieve electrodes are
applied to the proximal stump of the damaged PN, guiding nerve regeneration to the
distal end. This design, as the name implies, is thin polymeric insulating (such as
kapton) which has many holes machined into the film. These holes are than plated
and provide contacts to the regenerated PN, the conduit (spanning from proximal to
distal end of the PN) has conductive tracks which are wired to external connection
sites.6, 9, 11 However the materials used for these electrodes have moduli on the
order of GPa and the elastic moduli of a PN is ~0.45 MPa.12
Due to the incompatible material mismatch, limited device lifetime and the
need to develop a more compatible PNI.12 Our research focus has looked at using
polymers like polybutylene fumarate (PBF) and polydimethylsiloxane (PDMS), both
have lower modulus of elasticity relative to previously used silicon, glass, or metal.
As well as material selection, fabrication is carried out via the inexpensive
techniques of electrospinning13 and DLP® based projection microstereolithography
(PµSL)14 as described in chapter 6 to produce a flexible, porous conducting
polymeric patch design (Figure 7.1)
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2. Materials and Methods
2.1. Chemicals and Reagents
Polybutylene fumarate (PBF) was synthesized according to previously
reported procedures, and as described in Chapter 3.15 Phenylbis(2,4,6trimethylbenzoyl)phosphine oxide (BAPO), 97% and tetrahydrofuran (THF) were
purchased from Sigma. Nitric acid was purchased from Fisher Scientific.
Methacryloxypropyl terminated polydimethylsiloxane (PDMS-MA) and hydroxyl
terminated polydimethyl siloxane (PDMS-OH) were purchased from Gelest. All
chemicals were used as received from suppliers.

2.2 Equipment
A syringe pump (KD scientific,model 100s), stainless steel blunt-tip
needles (Small Parts) and a high voltage source (Glassman High Voltage, Series
EL) were used in the general electrospinning setup. Scanning electron
microscopy (SEM) was carried out using a Zeiss Supera 55VP and aFEI DB235.
Optical images were obtained using an Amiscope® microscope and images were
analyzed using NIH software ImageJ®.

2.3. Polymer Synthesis
2.3.1. Polydimethylsiloxane Sol-gel
Silanol terminated polydimethylsiloxane (PDMS-OH), tetrahydrofuran
(THF), tetraethyl orthosilcate(TEOS) and nitric acid were mixed to prepare a
PDMS-solgel solution, following a previous established protocol.16 Briefly,
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PDMS-OH was condensed with TEOS using an acidic catalyst (nitric acid) in a
THF solution at 80 °C for 40 min, producing a viscous PDMS sol-gel solution.
This was the precursor solution used for electrospinning.

2.3.2. Poly(butylene fumarate) (PBF)
PBF was prepared as described previously, detailed in Chapter 3 from ring
opening polymerization (ROP) from maleic anhydride (MA) and 1,3-butanediol
(BD).

2.4. Polymer Processing
2.4.1. General Electrospinning Procedure
All polymer solutions were delivered at a constant rate via a syringe pump
through a syringe fitted with a stainless steel blunt tip needle. The needle was
charged through a high voltage supply, and the resulting polymer fibers were
collected on a grounded target (6 x 6 in2 Cu plate fitted with Al foil). The grounded
target was equipped with a resistive Minco® heater. A UV source (UVP, BlakRay long wave ultraviolet lamp, model B100AP, λ = 365 nm) was used to
crosslink in situ.

2.4.1.1. Electrospinning PDMS Sol-gel
A 15% PDMS sol-gel dissolved in THF was delivered at a constant rate of
15 mL/hr, via a syringe pump through a 2 mL plastic syringe (inner diameter =
4.64 mm) fitted with a 1.5 inch 20 gauge stainless steel blunt tip needle (Small
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Parts, Inc.). The needle was charged at 20kV and the resulting polymer fibers
were collected on the grounded target, fitted with a Minco® resistive heater at a
distance of 20 cm from the end of the tip to create an electric field of 1kV/cm.
The Minco® heater allowed for the crosslinking condensation reaction to
continue and form individual fibers (Figure 7.2).

2.4.1.2. Electrospinning PBF
A 3% (w/w) initiator (phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide
(BAPO)) 75% (w/w) PBF dissolved in chloroform (CHCl3) was delivered at a
constant rate of 0.1 mL/hr, via a syringe pump through a 2 mL plastic syringe
(inner diameter = 4.64 mm) fitted with a 1.5 inch 20 gauge stainless steel blunt
tip needle (Small Parts, Inc.). The needle was charged at 15 kV and the resulting
polymer fibers were collected on the grounded target at a distance of 15 cm from
the end of the tip to create an electric field of 1kV/cm. A UV source was used to
crosslink polymer solution in-situ creating individual polymeric fibers (Figure 7.2).

2.4.2. General Projection Micro-StereoLithography (PµSL)
The PµSL apparatus is comprised of 1) a computer containing the
corresponding PowerPoint® slide of black and white images to serve as the
“mask” for printing the specified geometries, 2) a DLP projector (Acer Model
DSV008), 3) a converging lens with 15cm focal distance (Edmund Optics) and
finally 4) a stage which a silicon chip is placed to serve as a substrate to print the
structure on to (Figure 7.3).
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2.4.2.1. Printing Methacryloxyproply terminated Polydimethylsiloxane (PDMSMA)
A solution of phenylbis(2,4,6-trimethylbenzoyl)-phophine oxide (BAPO)
(.09g) was dissolved in 900µl of chloroform which was than added to 3g PDMSMA and mixed. A silicon chip was then placed on the stage of the PµSL
apparatus where the PDMS/BAPO solution (600 µl) was added and allowed to
self level before exposure to light from the projector (2 min). After allowing the
solution to level, it was exposed for 60 seconds followed by a developing step.
The structure was than crosslinked further (5 min) under UV (Black-Ray®, λ=
365 nm).

2.5. Printed PDMS-MA substrate evaluation
2.5.1. PµSL Setup verification
A projection mask was drawn in PowerPoint® with a varying size circles
(0.1 to 0.02 inch), which was reduced by optics. In order to determine the
smallest feature size that could be obtained with the constructed set-up. In
conjugation with varying hole size, the developer used was also evaluated for
efficiency. Optical images were taken of each printed substrate using
DinoScope® followed by analysis using ImageJ software® (NIH).
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2.5.2. Dynamic Mechanical Analysis (DMA)
Substrates were printed using a projection mask to produce PDMS strips
(thickness ~0.8 mm, width ~ 0.08 mm), the strips where tested by holding the
samples at physiological temperature (37°C) under controlled force (3 N/min to
18N). The modulus was determined by using Microsoft Excel® to determine the
slope within the linear region.

2.6. Animals Specimen
This study used 8-month-old retired breeder Sprague-Dawley male rats
(Charles River Laboratories, Wilmington, Mass.) that were housed individually in
a pathogen-free animal facility accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care and the National Institutes of Health. All
procedures were approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of Texas MD Anderson Cancer Center. Animals had
free access to food and water and were housed in individual cages in rooms that
were maintained at 21 °C, with 12-h light and dark periods.

2.6.1. Scaffold Implantation Procedure
A rat hind-limb, peroneal nerve model was used in all experimental
implantation procedures. PBF and PDMS implants were sterilized using ethylene
oxide several days prior to the implantation procedure. For all surgical
procedures, rats were given an anesthetic cocktail (64 mg/mL ketamine HCl, 3.6
mg/mL xylazine, and 0.07 mg/mL atropine sulfate), which was injected
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intramuscularly. Isoflurane 0.5–2% was used as a supplementary perioperative
anesthetic as required. After anesthesia was induced, the animal’s left thigh was
shaved, prepped with Betadine solution, and then draped sterilely. The peroneal
nerve was accessed by making a diagonal skin incision 25 mm proximal to the
knee. The overlying muscle was split parallel to the muscle fibers to reveal the
peroneal nerve. The nerve was cleaned of its perinerual tissue for a short
distance before dividing the nerve perpendicular to the axis of the nerve. The
material tobe implanted was hydrated with saline in a Petri dish at the start of the
procedure. The material was trimmed to the approximate diameter of the nerve
under an operating microscope and then implanted between the cut ends of the
peroneal nerve. The ends of the nerve were sutured together using 11-0 nylon
suture. Small segments of 4-0 polypropylene suture were cut and one placed
under the nerve about a centimeter above and below the implant to facilitate
locating the implant at the time of implant-nerve harvest (Figure 7.4).

2.6.2. Implant-Nerve Harvest Procedure and Histology
Three weeks after surgery, all rats were euthanized with CO2 asphyxiation
according to IACUC protocol. The left and right thighs were shaved. Using the
operating microscope, the implant-nerve specimens were located and harvested
by cutting the nerve 1-1.5 cm above and below the implant and placed in formalin
for histology. All specimens were fixed in paraffin blocks and cut with a
microtome at 8 micons thickness. Specimens were placed on glass slides and
stained with either hematoxylin and eosin (H&E) or Hirano-Zimmerman stains
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before being read by an unbiased veterinary pathologist.

3. Results and Discussion
3.1. Electrospun Porous Mats
Non-woven porous mats of poly(butylene fumarate) (PBF) and
poly(dimethyl siloxane) PDMS were created using modified electrospinning setups in our laboratory. PDMS was spun using a dilute stock solution of the
starting PDMS sol-gel and crosslinked thermally with the use of a Minco®
resistive heater, which enabled the material to be heated to high temperatures
(~250 °C) when contact was made on the grounded stationary collection plate.
Successful electrospinning of PBF was accomplished following the
methodology described in Chapter 6, allowing for in situ crosslinking to occur as
it is spun and collected on the grounded collection plate. Evaluation of the mat
morphology was carried out using scanning electron microscopy (SEM) (Figure
7.5). Mat thickness was measured to be ~100 µm and ~300 µm for the PDMS
and PBF mats, respectively.

3.1.1. Electrospun (Espun) Mat Implantation and Evaluation
Our collaborators at MD Anderson Cancer Center (MDACC) (Gregory
Reece and Patrick Lin) implanted both the PBF and PDMS espun mats in a rat
hind-limb peroneal nerve model. Once the materials were implanted, the rats
were housed and maintained for three weeks, after which the animals were
sacrificed and the PDMS and PBF mats were transected from the specimen for
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further evaluation.
Histological evaluation of the implant (espun mat)/ nerve interface
included hematoxalin and eosin (H&E) and Hirano-Zimmerman staining. Both
staining procedures require paraffin embedding of the extracted implant/nerve
sample, PBF espun material is more brittle than that of PDMS and while samples
were being prepared some breakage was observed. The H&E staining of the
PBF mat/nerve interface (Figure 7.6) showed this PBF mat breakage as well as
limited infiltration in the relatively thick espun mat as compared to the HiranoZimmerman stained PDMS mat/nerve interface (Figure 7.7). Due to the poor
infiltration of the electrospun scaffolds and alternative technique was sought out.

3.2. Projection Micro-StereoLihography (PµSL):Set Up and Verification
Initial material performance, as evaluated by the electrospun implants,
sparked interest in moving forward with PDMS as the implant material. The
moduli of PDMS can range from 1.76 – 13.9 MPa17 and has a much lower moduli
compared to other materials being evaluated as peripheral nerve interfaces
(PNI). However the PDMS sol-gel precursor solution used in electrospinning was
not suitable to be printed by the inexpensive technique of PµSL. The need for a
different PDMS precursor solution was due to the caveat that the PDMS
precursor solution must contain a double bond to allow for patterning. To
address this requirement, we identified a methacryloxypropyl terminated
polydimethylsiloxane (PDMS-MA) which contains two terminal methacrylate units
and therefore can be crosslinked photchemically with BAPO.
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Our in-house PµSL setup was assembled as previous described by Fang

et al14, with the slight modification of removing the reflecting mirror and projecting
the image directly into the crosslinkable solution, which allowed for removal of
the trapezoidal effects seen from the projector itself (Figure 7.3). This system
includes a computer and LCD/DLP projector which was used to display a
MicrosoftPowerpoint® (ppt) presentation containing an image of regular pores,
which inturn allows the user to dictate the resulting substrate composition,
including porosity.
In order to identify the appropriate crosslinking and developing parameters
which were necessary for the PDMS-MA system a mask was made with 5
different circle sizes, ranging from a diameter of 0.1 inches to as small as .02
inches (2540 – 508 µm) (Figure 7.8). Using this mask and the PuSL procedure
was carried out as described in the methods section, the polymer was exposed
for 45 seconds and then developed in various solvents. These solvents included
toluene, hexanes, dichloroethane (DCE), water and a combination of solvents as
a post crosslinking development step were evaluated. All of the resulting
substrates were than optically imaged (Figure 7.8) and using Image J® the
minimum pore size was determined to be 79 µm from the development step
involving a brief rinse with toluene, followed by a water rinse. This resulted in a
6.4 × reduction in size from the image created by the projection mask.

3.2.1. PµSL Patterned Substrate Implantation and Evaluation
Once the PDMS-MA patterning parameters were established, patterned
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strips 8 mm x 8 mm (width x thickness) were patterned and the moduli of the
printed PDMS was calculated to be 9.13 ± 2.17 MPa by DMA. Next, patterning
of a continuous porous thin film substrate was carried out and implanted into the
same rat hind-limb pereonal nerve model as the espun PDMS sol-gel mat (Figure
7.4). The rats were maintained again for 3 weeks, upon completion the rats were
sacrificed and the patterned PDMS substrate/nerve area of interest was
extracted for H&E staining. Optical images of the implant/nerve area show nerve
growth through the holes of the substrate, proximal to distal (Figure 7.9) relative
to the less porous espun PDMS material that was first implanted.

4. Conclusions
Both inexpensive techniques of electrospinning (espin) and projection
micro-stereolithography (PµSL) have been employed to create porous networks
to study feasibility for a material to meet the requirements for peripheral nerve
interfaces (PNI). Both PBF and PDMS were evaluated as potential materials at
the start with initial expermiments on espun mats, promise in PDMS was seen as
it was more flexible over the stiffer PBF espun mat. Using PDMS as the material
offers a better material nerve moduli match over the mismatched materials that
are currently used in PNI (Silicon).
Greater nerve infiltration was seen with the controlled porosity PDMS
materials that were patterned through the use of PµSL using photo crosslinkable
PDMS-MA. Initial in vivo studies in the rat hind-limb peroneal nerve model have
indicated the potential to use a PDMS patterned membrane as a suitable
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interface material. Movement towards an electrically active PDMS is currently
being explored. This includes producing PDMS PµSL patterned substrates with
the inclusion of multi-walled carbon nano-tubes (MWCNTs), carbon black and
many other fillers/additives.
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Scheme 7.1. Synthetic routes to produce PDMS-sol gel from silanol terminated
PDMS (1), TEOS (2) and nitric acid (H+) (A) and crosslinking of PDMS
methacrylate terminated (PDMS-MA) by BAPO for PµSL (B).
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Figure 7.1. Schematic representing polymeric patch design. The patch will be
inserted in the nerve (between distal and proximal ends), consisting of pores,
conducting electrodes and wires to feedback signals.
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Figure 7.2. Schematic of modified electrospinning setups. Each setup is
comprised of a 1) syringe pump, 2) high voltage source and 3) grounded
collection plate. To spin PBF a UV source is added in-line to crosslink the
photoinitator/polymer solution in situ (A) and to spin PDMS-sol a Minco® heater
and variac are added to the general setup (B).
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Figure 7.3. Schematic of projection microstereolithography (PmSL) setup. The
system is comprised of a 1) computer, 2) DLP projector, 3) converging lens and
finally a 4) stage.
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Electecrospun Scaffold (ES)

100µm

5mm

PµSL Printed Substrate

Figure 7.4. Schematic of rat hind-limb peroneal nerve model and implant
procedure. Where the material, either electrospun scaffolds (PDMS or PBF) or
PµSL substrates (PDMS) were implanted.

Figure 7.5. As spun PDMS sol-gel (left) and PBF (right) electrospun mats.
Scale bar is 100µm and inset 20µm,
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Figure 7.6. H&E staining of PBF implant/nerve interface. The PBF implant (*),
was fractured during histological prep and is seen in the magnified image (B).
Scale bar is 100 and 50 µm, respectively.
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50 µm

Figure 7.7. Hirano Zimmerman staining of PDMS implant/nerve interface.
Implant (*) and the nerve implant boundary ( - - ) can be visualized. Scale bar is
50 µm.
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Figure 7.8. Schematic of the mask created in PowerPoint® to generate circles
of 5 different diameters (2540 – 508 µm) (left) and an optical image of the
resulting crosslinked PDMS-MA network. Scale bar 1 mm.

A

B

Figure 7.9. Optical image of porous PDMS PmSL printed sheet (A), and H&E
histology after 21 days in the rat peroneal nerve (B), where the inset is a low
magnification image of the nerve-implantation site (nerve fibers (+), nylon suture
(*), plane of implant (- -) and proximal to distal (å)). Scale bar 1 mm.
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Part II: Printed Poly(Dimethyl Siloxane) Substrates with Controlled Pore
Size: Studying Flap Revascularization in and Ischemic Mouse Model

1. Introduction
Angiogenesis, or the generation of new blood vessels from existing
vasculature, is crucial for the realization of functional engineered tissues. As new
tissues grow, the (resident or involved or active) cell populations must have
immediate access to a blood supply for the delivery of nutrients and removal of
waste products. Therefore, the success of a tissue engineering construct is
dependent not only its ability to assist in the generation of the tissue of interest,
but must also always (support) the neo-tissue with a healthy vascular network.1, 2
The need for a strategy to promote revascularization is apparent and
researchers have begun to explore scaffolding parameters for this task. Scaffold
parameters such as overall void volume as well as pore shape, size, and
tortuosity are a few of the variables examined to date.3 With each of these
variables potentially influencing the overall angiogenic potential of a scaffold, it
can be a daunting task to optimize the scaffolding geometry.
To study angiogenesis, murine (mouse) models are the most common
wound healing models as mice are inexpensive to house.4 Despite differences in
epithelial architecture between human and mouse skin, the model is versatile
and provides an effective genetic manipulation platform.5, 6 Among the mouse
skin models available, ischemic models offer significant advances over other
models in studying and elucidating signaling roles in angiogenesis and
vasculogenisis (vessel formation from circulating endothelial progenitor cells) due
to the increased influx of cytokines and elevated protease levels. 7, 8
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A frequently used model, the myocutaneous flap model (flap consisting of

skin and muscle), has been developed to produce an ischemic gradient.
Ischemia is a potent stimulus for new blood vessel formation, establishing
capillary growth and restoring the appropriate oxidative conditions.9 Recently,
this reproducible ischemic model has been employed at UNM by our collaborator
Dr. Thomas Howdieshell to investigate a non-invasive technique to monitor
revascularization.10 This technique, full-field laser perfusion imaging (FLPI),
allows for mapping of flow fields and produces a speckled high contrast image of
blood flow within the flap.11, 12 It has been demonstrated that if a material is not
placed between the skin flap and underlying tissue, revascularization will occur.10
However, if a nonporous implant is introduced, there is a inhibitory effect on
engraftment and revascularization, and the distal flap will show signs of ischemic
necrosis. Thereby providing an in vivo model which can be used to “tease” out
the effects of a materials ability to promote angiogenesis.
Since there are many structural parameters to examine, we have decided
to look at the bioinert material polydimethylsiloxane (PDMS), as it is similar to
silicone used in the previous study and will not undergo degradation. In order to
control the implant geometry and composition, we have chosen to use the
inexpensive rapid prototyping (RP) technique of projection
microstereolithography (PµSL). As discussed in Chapter 6, PµSL uses
computer-controlled light projection to spatially control solidification of a liquid
photo-polymerizable resin.13 Structural parameters such as pore size,
configuration, and gradient density can be freely varied with little effort and cost.
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Here in, we look at the effect of controlled pore size on flap

revascularization. To carry out this goal, we have fabricated PDMS printed
implants with and without pores for implantation in the myocutaneous flap model.
We monitored the perfusion of the flap throughout the study period by the noninvasive FLPI technique, followed by histological testing of the
flap/implant interface at the termination of the study.

2. Materials and Methods
2.1 Chemicals and Reagents
Phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide (97%, BAPO) was
purchased from Sigma. Methacryloxypropyl terminated polydimethylsiloxane
(PDMS-MA) was purchased from Gelest. All chemicals were used as received.

2.2. Equipment
A projection microstereolithography system (PµSL) was built in-house as
described in Chapter 6. Optical images were obtained using an Amiscope®
microscope and images were analyzed using NIH software ImageJ®. Full-Field
Laser Perfusion Imager (FLPI) was purchase from Moor Instruments (Essex, UK).

2.3. Printing Methacryloxyproply terminated Polydimethylsiloxane (PDMS-MA)
A solution of phenylbis(2,4,6-trimethylbenzoyl)-phophine oxide (BAPO) (0.09
g) was dissolved in 900 µl of chloroform which was then added to 3 g PDMS-MA and
mixed. A silicon chip was then placed on the stage of the PµSL apparatus where
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the PDMS/BAPO solution (600 mL) was added and allowed to self level before
exposure to light from the projector (2 min). After allowing the solution to level, it
was exposed for 60 seconds followed by a developing step. The structure was than
crosslinked further (5 min) under UV (Black-Ray®, λ= 365nm).

2.4. Animals Specimen
This study used 8-12 week old C57BL6 mice (Jackson Laboratories, Bar
Harbor, Maine) that were housed individually in a pathogen-free animal facility in
accordance with the National Research Council’s “Guide for the use and care of
laboratory animals.” All procedures were approved the University of New Mexico’s
animal review committee. Animals had free access to food and water and were
housed in individual cages in rooms that were maintained at ambient temperature,
with 12 hour light and dark periods.

2.4.1. Scaffold Implantation Procedure
A previously identified mouse myocutaneous flap model was used in all
experimental implantation procedures.10 Briefly, PDMS implants were sterilized
using Sterrad® hydrogen peroxide autoclaving several days prior to the implantation
procedure. For all surgical procedures, mice were given anesthesia in the form of
Isofluorane®, which was administered via nose-cone inhalation and maintained
throughout scaffold implantation. Upon induction and maintenance of anesthesia,
back skin hair was removed via electronic clippers followed by surgically prepping
with povidone-iodine and alcohol. Once prepped, a peninsular-shaped flap was
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created surgically (approximately 3.0 cm in height by 1.5 cm in width, in a
rectangular shape). The control mice (no implant, n = 3) were immediately sutured to
close the flap. Mice (n = 6) to receive scaffolds underwent insertion of 3.0 x 1.5 cm
trimmed implants of solid crosslinked PDMS sheets (S, n =3) or porous crosslinked
PDMS (SP, n = 3) before closure of the flap.

2.4.2. Full-Field Laser Speckle Perfusion Imaging (FLPI)
At 0, 2, 5 and 10 days after surgery, each mouse underwent Isoflourane®
anesthesia, and each mouse (control, S, or SP) underwent FLPI perfusion analysis
at 20 cm camera distance in low resolution/high speed setting at a display rate of 25
Hz, time constant of 0.1 s, and camera exposure time of 20 ms, and images were
collected and recorded electronically. Perfusion is determined as an arbitrary unit,
PU, based on calibration to a reference flux measurement of polystyrene beads in
water undergoing thermal Brownian motion.12

2.4.3. Implant-Tissue Harvest and Histology
10 days after surgery, all mice were euthanized with CO2 asphyxiation
followed by cervical dislocation according to the institutional animal review board
protocol. The entire flap was excised (ie. implant included) for examination. All flaps
harvested were transected into cranial and dorsal sections that corresponded to
FLPI orientation carried out at the previous time points (0, 2, 5 and 10 days).
Specimens were then fixed in IHC Zinc fixative (BD Biosciences, San Jose, CA)
overnight followed by paraffin embedding and cut to 5 micron thick slices by
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microtome. Histologic sections were imaged by hematoxylin and eosin (H&E)
staining (morphology), CD-31 immunohistochemistry (vessel density), and F4/80
immunohistochemistry (macrophage density and location). Our collaborator, Dr.
Thomas Howdieshell of UNM Health Sciences Department of Surgery, then
photographed and analyzed the images of each specimen for morphology,
microvascular density, and macrophage localization.

3. Results and Discussion
3.1. Substrate Fabrication
Previous work by McGuire and Howdieshell, investigated importance of flap
engraftment for revascularization by looking at an ischemic cranial-based
myocutaneous flap model with and without silicone sheets inserted. (JSurg ref) As
medical grade silicone (MedSi) was used in the previous flap study,
methacryloxyproply terminated polydimethylsiloxane (PDMS-MA) was chosen for its
similar material properties as well as our previous experiencing printing patterned
PDMS-MA thin films via projection microstereolithography (PµSL).14 Substrates of
PDMS with (SP) and without (S) pores were patterned using our in-house PµSL
setup described in Chapter 6. Masks to create S and SP substrates of 1.5 x 3.0 cm
(width x length) was created in PowerPoint ® followed by patterning of PDMS-MA.
The methacrylate unites of PDMS-MA were crosslinked using the photoinitiator
phenylbis(2,4,6-trimethylbenzoyl)-phophine oxide (BAPO) and uncrosslinked PDMSMA was removed by a toluene and water rinse. Thin films were patterned (n=6) with
average thicknesses of 13.4 ± 0.1 µm (S) and 12.2 ± 0.1 µm (SP), which are similar
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to the medSi thickness of 10.6 ± 0.1 µm. SP films had an average pore size of 271
± 1 µm with horizontal spacing of 490 ± 1 µm and 602 ± 1 µm vertical spacing (7.10).

3.2. Scaffold Implantation and Evaluation
Upon completion of patterning S and SP substrates, creation of a
myocutaneous flap model in C57BL6 mice was carried out. There were three
models, including 1) flap only, 2) flap with underlying S inserted and 3) flap with
underlying SP inserted (Figure 7.11). After substrate implantation, mice were
subjected to full-field laser speckle perfusion imaging (FLPI) as well as at 2, 5 and
10 days while maintaining anesthesia. Throughout the study the flap area was also
visually observed followed by termination of the study at day 10. On day 10 mice
were sacrificed via CO2 asphyxiation and the implant/flap was harvested and
histology was preformed.

3.2.1. Laser Speckle Perfusion Imaging (FLPI)
This non-invasive and no contact technique provided a method to map flow
fields of blood flow by illuminating the area of tissue with laser light, producing a high
contrast speckle pattern. Perfusion was measured cranial to caudal, focusing on
regions of interest (ROI) throughout the implant/flap area (cranial, central and
caudal) (Figure 7.12). These ROI were selected in order to span the gradient
ischemic flow that is introduced from this model.10 Prior to flap creation, imaging
showed uniform perfusion across all of the mice selected for this study at ~300-325
perfusion units (PU) (Figure 7.13). Upon closure specimens were again imaged and
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the lack of perfusion can be visualized and compared to the control or pre flap
creation and is seen as there was a decrease in PU’s corresponding to postoperative measurements (Figure 7.13).
Gross visualization of the flap with S inserted showed caudalflap necrosis
over the 10 day period (data not shown) that was also confirmed by speckle
imaging. Looking at Figure 7.3 of the speckle imaging for S implant mice shows
large areas of white at both day 5 and 10 (indicated by thin white arrows). This is in
line with the visualization of caudal flap necrosis seen by the naked eye, as red
indicates high perfusion and minimal perfusion is indicated by blue. In contrast,
mice with SP implants showed no visual ulcers or necrotic signs and through FPLI
high perfusion areas (red) were observed and there was a lack of minimal perfusion
(blue) observed as compared to the non-porous S implants (Figure 7.12). Analysis
of the ROI and plotting the perfusion at for each day (Figure 7.13) further confirms
the difference in implant (S or SP) performance. In both specimen groups had a
decrease in perfusion across all ROI’s. However in the specimens with S implanted,
the perfusion for all ROI’s (cranial to caudal) increased at day 2 followed by a
continued decrease seen at day 5 and day 10 in the central and caudal ROI’s
(Figure 7.13). This was not the case for SP specimens, Figure 7.13 shows
significant increase in perfusion over the course of the study in a similar fashion to
the control specimens.

3.2.2. Implant-Tissue Harvest and Histology
Excision of the flap-implant showed the effect of implant selection on
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engraftment, further confirming the observations that were seen with the noninvasive FLPI results. Specimens with S implants show no flap engraftment, and the
substrate is completely unattached to the flap upon removal. However, integration
of the SP implants can be seen visually and the implant is attached to the flap tissue
(data not shown). After excision of the full flap it was sectioned to directly
correspond to the cranial, central and caudal ROI’s that were assigned in the
speckle imaging. Samples were then fixed and paraffin embedded (Tricore Labs,
NM) followed by hematoxylin and eosin (H&E), CD-31 and F4-80 immunostaining.
Distal flap H&E of non-porous (S) reveled an attenuated panniclus carnosus
muscle with evident necrosis of multiple muscle bundles due to persistent ischemia
and lack of revascularization (Figure 7.14). In contrast, porous (SP) revealed viable
panniclus carnosus muscle, with healthy dermis and epidermis of the growth through
the pore (tissue peg). The tissue peg bridged the granulation tissue to the
underlying muscle, several large blood vessels can be seen as well (Figure 7.14).
CD-31 immunostaining of the proximal flap of specimen with S implants
showed large blood vessels and viable panniculus carnosus muscle (Figure 7.14).
The proximal flap remains perfused by the specimens’ segmental vessels with
compensatory “arteriogenesis” attempting to provide perfusion of the distal flap,
which remains ischemic. This ischemia is due to the lack of neovascularization of
the recipient bed, which is being blocked by the S implant (Figure 7.14). However,
with the SP implant specimens there was no lack of neovascularization as the tissue
peg displayed multiple blood vessels in the panniculus muscle as well as in the
dermis and epidermis (Figure 7.14).
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Macrophage density and location, as stained by F4-80, revealed prominent

monocyte infiltration in granulation tissue deep into the non-porous implanted sheet
(Figure 7.14). Within the tissue peg of the SP specimen, monocyte infiltration was
marked into the muscle and beyond into the perivascular locations (Figure 7.14).

4. Conclusions
We have fabricated PDMS thin films via the inexpensive technique of PµSL
with or without pores. Using a myocutaneous mouse model we have shown that the
pores (SP) implants allowed for better perfusion over the solid (S) implants. The SP
implants also allowed for engraftment of the material to the flap. The combination of
both the mycutaneous flap mouse model and fabrication technique of PµSL presents
an inexpensive model to study de novo or induced vascularization in a mouse
model, further leading to solving the translational problem of tissue integration and
vascularization.
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Med Si

PDMS

PDMS porous

1 cm
Figure 7.10. Image of 1.5 x 3.0 cm (length x width) of as received medical grade
silicone (Med Si) and as printed PDMS non porous (S) and porous (SP). Optical
image of SP pores are visible in the accompanying zoomed in image (far right).
Scale bar 1 cm and 1 mm, respectively.

A

B

C

Figure 7.11. Schematic representation of myocutaneous flap surgical model and
the proposed specimens in this study. The control mouse (incision only) (A), mice
with S implanted (B) and SP implanted mice (C).
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Control
– flap

Control
+ flap

PDMS
- pores

PDMS
+ pores

Figure 7.12. Representative images of laser speckle (FLPI) images as obatained at
day 5 (left) and 7 (right )after implantation of the material (none, S and SP). The
speckle pattern displays differences in perfusion, a high perfusion (red) can be
distinguished from a low perfusion (blue). The flap incision boundary is represented
by the thick white arrows (ñ) and areas were there is lack of perfusion (ie. necrotic
or death of flap) are indicated by thin white arrows. All images are orientated from
caudal to cranial and the accompanying specimen is displayed.
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Control

PDMS -pores

PDMS + pores

Control

PDMS -pores

PDMS + pores

Figure 7.13. Perfusion (PU) can be quantified as a function of time by evaluating
the predefined regions of interest (ROI). Representative FPLI images are shown
above each perfusion chart.
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Figure 7.14. After specimens were sacrificed at Day 10 Samples were then fixed
and paraffin embedded followed by hematoxylin and eosin (H&E) (left), CD-31
(middle) and F4-80 (right) immunostaining. Image view of location is represented by
* on the corresponding mouse schematic.
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Chapter 8. Summary and Future Directions

8.1. Summary
The overall objective of this research was to development and
characterize a crosslinkable, biocompatible polymeric system with tunable
degradation for use in the fabrication of scaffolds for bone tissue engineering
applications. The first specific aim, synthesize and characterize a biodegradable
polymer system, was accomplished by leveraging the extensive knowledge gained
from the biomaterial poly(propylene fumarate) (PPF) since its first introduction in
1987 by Ibay et al.1, 2 Two synthetic routes were identified and followed to form the
homopolymer of poly(butylene fumarate) (PBF) and the copolymers poly(propylene
fumarate)-co-(propylene maleate) (PPFcPM) and poly(butylene fumarate)-co(butylene maleate) (PBFcBM). The first route, ring opening polymerization (ROP) of
maleic anhydride (MA) at high temperatures produced all fumarate containing
polymers (PBF). Low temperature routes limited the cis-trans isomerization of the
maleate functionality to fumarate yielding the copolymers PPFcPM and PBFcBM.3-5
With this method, however, the final polymer maleate to fumarate ratio was not
controllable. Due to this limitation, a second route starting from acid chlorides
(maleoyl chloride, MCl and fumaryl chloride, FCl) was developed and led to a
controlled fumarate to maleate ratio by controlling the stoichiometry through
monomer selection.
The second specific aim focused on PBF network characterization and in vitro
degradation. Initial studies were carried out to determine the extent of crosslinning
of photo crosslinked PPF and PBF networks. By using an efficient acyl phosphine
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photoinitator, phenylbis(2,4,6-trimethylbenzoyl)-phophine oxide (BAPO), highly
crosslinked networks were obtained. Accelerated degradation conditions confirmed
our hypothesis that the extra methylene unit in the backbone of PBF would allow for
an increased degradation rate over PPF without compromising the materials
crosslinkablilty, processability and mechanical suitability.
The third specific aim, validating in vitro cytocompatibility and osteogenic
differentiation of mesenchemyl stem cells (MSCs) on crosslinked networks of PBF
relative to PPF was carried out using previously established methods as described
by Timmer et al.6 It was found that there were no cytotoxic effects from incubation
with fumaric acid, however cells in constant contact with 1,3-butanediol displayed a
reduced cell number. The data also indicated the crosslinked substrates did not
have anything leachable that elicited a cytotoxic response on the murine
osteoprogenitor cell line of MC3T3-E1. In addition, cellular attachment, proliferation,
and osteoblastic differentitaion of mesenchymal stem cells on crosslinked PBF was
found to be similar to that of previously examined PPF Osteogenic differentiation
was monitored by evaluating the expression of the osteogenic marker alkaline
phosphatase (ALP) and matrix calcium deposition.
Finally, the fourth specific aim, using inexpensive processing techniques to
create 3D polymeric scaffolds, was accomplished through the development of new
methodology for electrospinning and projection microstereolithography (PµSL).
Developing an in situ crosslinking step to the general electrospinning technique
allowed the ability for crosslinking of low glass transition (Tg) materials such as the
fumarate-based polymers. Our results are the first to demonstrate rendering
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ofcontinuous fibers of PPF to produce a high surface area to volume porous mat for
tissue engineering applications. In addition, the inexpensive 3D printing technique of
PµSL offers a more affordable alternative to the more costly stereolithography
procedures. Both of these methodologies can be extended to similar classes of
polymers in order to produce prefabricated scaffold for potential clinical applications
in the field of not only bone tissue engineering, but tissue engineering in general.

8.2. Future Directions
8.2.1. Degradation
The inclusion of the methylene unit to produce poly(butylene fumarate) (PBF)
resulted in an increase in the degradation rate over the widely studied
poly(propylene fumarate) (PPF) when it was examined under accelerated
degradation conditions. The other engineered polymer modification, the introduction
of the maleate functionality in the polymer backbone, was examined in order to
create a polymer with tunable degradation kinetics without sacrificing mechanical
suitability of the crosslinked network. A feasibility study where poly(butylene
fumarate)-co-(butylene maleate) (PBFcBM) containing 33 mol% maleate was
subjected to physiological in vitro degredation conditions (1X PBS @ 37 °C) showed
that the rate of ester hydrolysis was altered (Figure XX). The results of this study
verified that the “kinks” introduced by the addition of the maleate would allow for an
increased rate of degradation. Promising results obtained from the in vitro
degradation of PBFcBM allowed for the development of the controlled synthesis of
PBFcBM, as detailed in Chapter 4. Future studies will need to be carried out in

	
  

	
  

141

order to determine the direct effect of maleate concentration in the polymer
backbone and its effect on rate of ester hydrolysis. All polymer formulations will be
explored via in vitro and in vivo physiological degradation conditions to determine
long term performance.

8.2.2. Three Dimensional (3D) Substrates
With our recent method development to electrospin low glass transition (Tg)
fumarate-based polymers, the ability to produce biomimetic relevant high surface
area to volume porous mats of nano to micron sized fibers can be produced via the
inexpensive technique. Although the electrospinning process is an inexpensive
fabrication technique for the production of 3D scaffolds for tissue engineering
applications, there are many processing parameters that can be altered to effect the
resulting mat morphology.8 Due to this flexibility, further optimization of the
methodology presented in Chapter 6 is required.
Although electrospinning can produce highly nano to micron sized fibers
which are highly interconnected, the fiber density is a parameter that deserves
attention. The ideal scaffold which has found success in BTE applications is greater
than 90 % porous, but also has an optimal pore size of 100-350 µm.9, 10 Strategies
to increase the pore size of electrospun scaffolds (ES) have included increasing the
fiber diameter to increase the overall void volume in the scaffolds. 11 However, the
implementation of nanofibers has been shown to increase cell adhesion, proliferation
and aide in differentiation of stem cells.12 A composite mat of the fumarate-based
polymers could be electrospun using a multimodal design that was suggested by
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Soliman et al9 to yield a mat with a largely dense fiber morphology with smaller
densely distributed fibers dispersed throughout. Another strategy to alter porosity
would be to include post modification techniques; the easiest of these being the use
of a sacrificial polymer, one which would be cospun with our polymer and removed
after the scaffold was fabricated. Those which have been used previously include
poly(ethylene oxide) and gelatin, which are both soluble in aqueous conditions and
can be removed without causing structural damage to the polymer of interest (ie.
PPF or PBF).13
In addition to optimizing fiber diameter and porosity of the resulting
electrospun scaffolds (ES), the mechanical properties need to be evaluated.
Mechanical properties of the mat can be looked at under similar degradation
conditions as the solid crosslinked samples, looking at dimensional changes as well
as changes in moduli of the mat. Analysis of the as spun ES by themselves not only
is an area of future exploration, but also the cell interaction with/on the electrospun
mats to evaluate the mechanical properties as mesenchymal stem cells (MSCs)
undergo osteogenic differentiation and bone is laid down on the ES material in vitro
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